Breast Cancer Clinical Trials

Additional Locations :

An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)

Anniston : Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Birmingham : Updated

A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer

Birmingham : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Birmingham : University of Alabama at Birmingham

Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise After Preoperative Chemotherapy for Breast Cancer

View More »

Birmingham : University of Alabama - Birmingham

Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy

Birmingham : Bruno Cancer Center

Study of 0.1% Uracil Ointment (1UO) Ointment for the Prevention of Hand-Foot Syndrome

Birmingham :

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

Mobile : University of South Alabama / Mitchell Cancer Institute Deptof Mitchell Cancer Inst(2) Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Mobile : Providence Cancer Center at Providence Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Additional Locations :

An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)

Anchorage : Providence Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Fairbanks : Fairbanks Cancer Treatment Center at Fairbanks Memorial Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Additional Locations :

An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)

Chandler : Updated

A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer

Chandler : Ironwood Cancer and Research Centers Ironwood

A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation

Phoenix : Arizona Oncology Associates Dept of Oncology

A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation

Phoenix : Arizona Oncology Associates Dept of Oncology Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

View More »

Scottsdale : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Scottsdale : Scottsdale Medical Imaging, Limited (SMIL)

Collection of FUJIFILM's 3Dimensional Mammograms

Scottsdale : Mayo Clinic Arizona

Dose-escalation Study of Oral CX-4945

Scottsdale :

Study Evaluating the Safety and Efficacy of Onartuzumab (Metmab) And/Or Bevacizumab in Combination With Paclitaxel in Patients With Metastatic, Triple Negative Breast Cancer

Scottsdale : Pinnacle Oncology Hematology

Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors

Sedona :

A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Patients With Locally Recurrent or Metastatic Breast Cancer

Tucson : Updated

A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer

Tucson : University of Arizona

Excision Followed by Radiofrequency Ablation for Breast Cancer

Tucson : Research Site

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

Additional Locations :

An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)

Fayetteville : Highlands Oncology Group Dept of Highlands Oncology Grp

A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With LCL161 in Patients With Triple Negative Breast Cancer

Fayetteville : Highlands Oncology Group Dept of Highlands Oncology Grp

A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation

Fayetteville : Highlands Oncology Group Dept of Highlands Oncology Grp Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Hot Springs : Updated

A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer

View More »

Hot Springs : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Jonesboro : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Jonesboro : Sandoz Investigational Site

Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim

Jonesboro : NEA Medical Clinic - East Matthews

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Little Rock : University of Arkansas for Medical Sciences

Excision Followed by Radiofrequency Ablation for Breast Cancer

Little Rock : University of Arkansas For Medical Sciences

Percutaneous Removal and Margin Ablation for Breast Cancer

Little Rock : Arkansas Cancer Research Center at University of Arkansas for Medical Sciences

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Springdale : The Center for Chest Care

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Duarte : City of Hope Updated

64 Cu-DOTA-Trastuzumab Positron Emission Tomography in Women with Advanced HER2 Positive Invasive Breast Cancer

Duarte : City of Hope Updated

A Pilot Study of the Impact of a Single Dose of Zoledronic Acid on Biomarkers in Breast Cancer

Duarte : City of Hope Updated

Adjuvant Therapy in Older versus Younger Women with Breast Cancer: Longitudinal Impact of Adjuvant Chemotherapy on Functional Status, Comorbidity and Quality of Life

Duarte : City of Hope Updated

Administrative Supplement to Expand NCI-Supported Community Outreach Capacity through Community Health Educators (CHEs) of the National Outreach Network

Duarte : City of Hope Updated

Characterization of Circulating Tumor Cells (CTCs) to Direct Pre-Operative and Systemic Therapy in Patients with Locally Advanced or Metastatic Stage IV Breast Cancer

Duarte : City of Hope Updated

ECOG E2108: A Randomized Phase III Trial of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer

Duarte : City of Hope Updated

Efficacy and Tolerability of Nanoparticle Albumin Bound Paclitaxel (Abraxane) in Patients 65 and Older with Metastatic Breast Cancer

Duarte : City of Hope Updated

Enhancing Psychosocial Well-Being Reproductive Age BRCA+ Women

Duarte : City of Hope Updated

Evaluation of Breast Cancer Patterns and Outcomes of Care

Duarte : City of Hope Updated

Expression of P16INK4a As a Predictor of Myelosuppression in Patients with Breast Cancer

Duarte : City of Hope Updated

Feasibility of a Supportive Education Program for Latina Breast Cancer Survivors

Duarte : City of Hope Updated

Genetic Epidemiology of Breast and Ovarian Cancers

Duarte : City of Hope Updated

Impact of Adjuvant Chemotherapy on Metabolic Syndrome Risk Factors in Breast Cancer Patients

Duarte : City of Hope Updated

Long Term Follow-Up After Breast Cancer

Duarte : City of Hope Updated

NSABP B-43: A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy

Duarte : City of Hope Updated

Older Breast Cancer Patients: Risk for Cognitive Decline

Duarte : City of Hope Updated

Phase II Trial of Neoadjuvant Chemotherapy with Carboplatin and NAB-Paclitaxel in Patients with Locally Advanced and Inflammatory Triple Negative Breast Cancer

Duarte : City of Hope Updated

PHII-117, NCI #8822: Phase II Study of Azacitidine and Entinostat (SNDX-275) in Patients with Advanced Breast Cancer

Duarte : City of Hope Updated

PHII-96 NCI#8264: Phase II Trial of Single Agent ABT-888 with Post-Progression Therapy of ABT-888 in Combination with Carboplatin in Patients with Stage IV BRCA-Associated Breast Cancer

Duarte : City of Hope Updated

Pro Inflammatory Cytokines and Neurobehavioral Symptoms in Women with Breast Cancer

Duarte : City of Hope Updated

Reducing Extremity Lymphedema through Axillary Lymphatic Preservation Surgery

Duarte : City of Hope Updated

RTOG 1005: A Phase III Trial of Accelerated Whole Breast Irradiation with Hypofractionation Plus Concurrent Boost Versus Standard Whole Breast Irradiation Plus Sequential Boost for Early-Stage Breast Cancer

Duarte : City of Hope Updated

Sister Survivor: Improving the Survivorship Care of African-American Women with Breast Cancer

Duarte : City of Hope Updated

SWOG S0812: Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer

Duarte : City of Hope Updated

SWOG S1007: A Phase III Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less

Duarte : City of Hope Updated

Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older with HER2 Positive Locally Advanced or Metastatic Breast Cancer

View More »

Additional Locations :

An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)

Arcadia : Shapiro & Stafford & Yee & Polanski Study Coordinator Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Bakersfield : Updated

A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer

Burbank : Updated

A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer

Burbank : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Burbank : Providence St. Joseph Medical Center Roy&Patricia Disney Fam Cancer Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Campbell : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Castro Valley : Valley Medical Oncology Consultants - Castro Valley

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Castro Valley : East Bay Radiation Oncology Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Concord : Cancer Care Center at John Muir Health - Concord Campus

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Corona : Sandoz Investigational Site

Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim

Duarte : GenBasix Incorporated

Blood Sample Collection and Health Information Collection From Patients With Invasive Breast Cancer and Their Brothers and Sisters

Duarte : City of Hope Comprehensive Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Encinitas :

A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Patients With Locally Recurrent or Metastatic Breast Cancer

Everett : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Fairfield : North Bay Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Fremont : Valley Medical Oncology

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Fresno : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Fresno : Fresno Breast Surgery

NBRST: Prospective Neo-adjuvant REGISTRY Trial

Fresno : Cancer Care Associates Dept.ofCancerCareAssoc. Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Fullerton : St. Jude Heritage Healthcare

PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

Fullerton : St. Jude Heritage Medical Group Virginia Crosson Cancer Center Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Grass Valley : Sierra Nevada Cancer Center at Sierra Nevada Memorial Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Greenbrae : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Greenbrae : California Cancer Care Marian Speciality

A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation

Greenbrae : Updated

Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

Hayward : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Hayward :

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

La Jolla : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

La Jolla : University of California-San Diego - Rebecca and John Moores Cancer Center

Adjunctive Efficacy Study Of The SoftScan® Optical Breast Imaging System

La Jolla : University of California San Diego UCSD 3 Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

La Jolla : University of California, San Diego Updated

Quantitative Subharmonic Breast Imaging

La Verne : Wilshire Oncology Medical Group

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Loma Linda : Loma Linda University Medical Center

Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer

Long Beach : Updated

A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)

Long Beach : Long Beach Memorial Medical Center

NBRST: Prospective Neo-adjuvant REGISTRY Trial

Long Beach : BreastLink

NBRST: Prospective Neo-adjuvant REGISTRY Trial

Long Beach : Coast Hematology Oncology Associates Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Long Beach : Breastlink Medical Group, Incorporated at Long Beach Memorial Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Los Angeles : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Los Angeles : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Los Angeles : University of California Los Angeles

PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

Los Angeles : University of California at Los Angeles Dept. of UCLA Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Los Angeles : Los Angeles Hematology/Oncology Medical Group LA Cancer Network Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Los Angeles : USC/Norris Comprehensive Cancer Center and Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Los Angeles : Cedars Sinai Medical Center

Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors

Martinez : Contra Costa Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Marysville : Tibotec Therapeutics - Division of Ortho Biotech Products, LP

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Merced : Mercy Cancer Center at Mercy Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Mission Hills : Research Site Updated

Video Impact on Neulasta Education

Monterey : Community Hospital of Monterey Peninsula

NBRST: Prospective Neo-adjuvant REGISTRY Trial

Mountain View : El Camino Hospital Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Newport Beach : Hoag Memorial Hospital Presbyterian

An Evaluation of a Self-contained Direct Digital Radiography System for Breast Specimen Imaging

Oakland : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Oakland : Bay Area Breast Surgeons, Incorporated

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Oakland : CCOP - Bay Area Tumor Institute

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Oakland : Larry G Strieff MD Medical Corporation

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Oakland : Epic Care - Oakland

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Oakland : Highland General Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Oakland : Alta Bates Summit Medical Center - Summit Campus

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Oakland : Tom K Lee, Incorporated

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Oakland :

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

Orange : University of California, Irvine Medical Center

Patient Controlled Tissue Expansion for Breast Reconstruction

Orange : St. Joseph Hospital Regional Cancer Center - Orange

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Oxnard : Ventura County Hematology and Oncology

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Oxnard : Ventura County Hematology and Oncology PMK Medical Group Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Pleasant Hill :

A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Patients With Locally Recurrent or Metastatic Breast Cancer

Pleasanton : Valley Medical Oncology Consultants - Pleasanton

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Pomona : The Office of Dr. Swarna Chanduri, MD

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Roseville : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Roseville : Sutter Roseville Medical Center

NBRST: Prospective Neo-adjuvant REGISTRY Trial

Roseville :

Study Evaluating the Safety and Efficacy of Onartuzumab (Metmab) And/Or Bevacizumab in Combination With Paclitaxel in Patients With Metastatic, Triple Negative Breast Cancer

Roseville :

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

Sacramento : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Sacramento : UC Davis Medical Center Updated

Computed Tomography Versus Standard 2D Mammography Versus 3D Tomosynthesis

Sacramento : Sutter Healthcare-Sacramento

Patient Controlled Tissue Expansion for Breast Reconstruction

Sacramento : University of California Davis Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Sacramento :

Study Evaluating the Safety and Efficacy of Onartuzumab (Metmab) And/Or Bevacizumab in Combination With Paclitaxel in Patients With Metastatic, Triple Negative Breast Cancer

Sacramento :

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

San Diego : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

San Diego : Sharp Oncology (Comprehensive Breast Care of San Diego)

Excision Followed by Radiofrequency Ablation for Breast Cancer

San Diego : Kaiser Permanente-San Diego

Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer

San Diego :

Study Evaluating the Safety and Efficacy of Onartuzumab (Metmab) And/Or Bevacizumab in Combination With Paclitaxel in Patients With Metastatic, Triple Negative Breast Cancer

San Francisco : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

San Francisco : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

San Francisco : University of California, San Francisco

Phase 1/2 Study of ThermoDox With Approved Hyperthermia in Treatment of Breast Cancer Recurrence at the Chest Wall

San Francisco : University of California San Francisco Updated

Phase 2 Study of the Monoclonal Antibody MGAH22(Margetuximab)in Patients With Relapsed or Refractory Advanced Breast Cancer

San Francisco : UCSF Helen Diller Family Comprehensive Cancer Center

Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib

San Francisco : University of California San Francisco Updated

Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer

San Francisco :

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

San Jose : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

San Jose : Good Samaritan Hospital, San Jose

Patient Controlled Tissue Expansion for Breast Reconstruction

San Jose :

Study Evaluating the Safety and Efficacy of Onartuzumab (Metmab) And/Or Bevacizumab in Combination With Paclitaxel in Patients With Metastatic, Triple Negative Breast Cancer

San Jose :

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

San Luis Obispo : Coastal Integrative Cancer Care Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

San Pablo : Doctors Medical Center - San Pablo Campus

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Santa Barbara : Sansum Clinic

Breast Cancer Biomarker Sample Collection for the dtectDx Assay Verification

Santa Barbara : Santa Barbara Hematolgy Oncology Medical Group Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Santa Clara : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Santa Clara :

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

Santa Maria : Central Coast Medical Oncology Corporation

PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

Santa Maria : Central Coast Medical Oncology Corporation Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Santa Monica : Premiere Oncology

Dose-Dense Chemotherapy Plus Bevacizumab in High Risk Lymph Node Positive Breast Cancer: A Pilot Study

Santa Rosa : Redwood Regional Medical Group

Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax

Santa Rosa : Research Site Updated

Video Impact on Neulasta Education

South San Francisco : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

South San Francisco :

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

Stanford : Updated

A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer

Stanford : Updated

A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)

Stanford : Stanford University - Stanford Breast Imaging Center

Adjunctive Efficacy Study Of The SoftScan® Optical Breast Imaging System

Stanford : Stanford University Updated

Phase 2 Study of the Monoclonal Antibody MGAH22(Margetuximab)in Patients With Relapsed or Refractory Advanced Breast Cancer

Sylmar : University of California at Los Angeles

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Sylmar : Updated

Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

Truckee : Tahoe Forest Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Valencia : Granada Hills Cancer Center Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Vallejo : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Vallejo :

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

Walnut Creek : John Muir/Mt. Diablo Comprehensive Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Walnut Creek :

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

West Hills : Wellness Oncology Hematology

NBRST: Prospective Neo-adjuvant REGISTRY Trial

Whittier : Presbyterian Intercommunity Hospital

NBRST: Prospective Neo-adjuvant REGISTRY Trial

Additional Locations :

An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)

Aurora : University of Colorado Cancer Center

PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

Aurora : Aurora Presbyterian Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Aurora :

Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer

Boulder : Boulder Community Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

View More »

Colorado Springs : Penrose Cancer Center at Penrose Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Colorado Springs : Memorial Hospital Cancer Center - Colorado Springs

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Denver : Updated

A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer

Denver : Updated

A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer

Denver : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Denver : CCOP, Colorado Cancer Research Program, Inc.

Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer

Denver : Rose Medical Center

Dual-energy Contrast-enhanced (2D and 3D Mammography Versus Contrast-enhanced MRI)- A Pilot Study

Denver : CCOP - Colorado Cancer Research Program, Inc.

Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer

Denver : Kaiser Permanente Northwest Kaiser Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Denver : St. Anthony Central Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Denver : Rose Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Denver : Presbyterian - St. Luke's Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Denver : CCOP - Colorado Cancer Research Program

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Denver : Porter Adventist Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Denver : St. Joseph Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Englewood : Swedish Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Fort Collins : Front Range Cancer Specialists

Dose-escalation Study of Oral CX-4945

Fort Collins : Front Range Cancer Specialists

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Fort Collins : Poudre Valley Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Grand Junction : St. Mary's Cancer Center St Mary's Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Grand Junction : St. Mary's Regional Cancer Center at St. Mary's Hospital and Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Greeley : North Colorado Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Greenwood Village : Rocky Mountain Cancer Centers RMCC Hale Pkwy

A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation

Greenwood Village : Rocky Mountain Cancer Centers RMCC - Denver-Midtown Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Littleton : Littleton Adventist Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Lone Tree : Sky Ridge Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Longmont : Hope Cancer Care Center at Longmont United Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Loveland : Front Range Cancer Specialists

Dose-escalation Study of Oral CX-4945

Loveland : McKee Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Parker : Parker Adventist Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Pueblo : St. Mary - Corwin Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Thornton : North Suburban Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Wheat Ridge : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Wheat Ridge : Exempla Lutheran Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Bridgeport : Bridgeport Hospital

A Phase II Study of Rapamycin and Trastuzumab for Patients With HER-2 Receptor Positive Metastatic Breast Cancer

Bridgeport : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Hartford : Hartford Hospital

Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer

Hartford : Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Many locations :

An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)

View More »

Middletown : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

New Haven : Yale Comprehensive Cancer Center at Yale University School of Medicine

A Phase II Study of Rapamycin and Trastuzumab for Patients With HER-2 Receptor Positive Metastatic Breast Cancer

New Haven : Yale University, Yale Cancer Center

Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer

Norwalk : Updated

A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer

Norwich : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Stamford : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Waterbury : Waterbury Hospital Health Center

Computed Tomography Laser Mammography Breast Imaging Device

Additional Locations :

An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)

Lewes : Tunnell Cancer Center at Beebe Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Newark : Helen F. Graham Cancer Center

Ph I Dose Escalation Study of Antibody-drug Conjugate IMMU-132 in Patients With Advanced Epithelial Cancers

Newark : CCOP - Christiana Care Health Services

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Washington : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Washington : Updated

A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer

Washington : GSK Investigational Site Updated

ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D

Washington : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Washington : Georgetown Lombardi Comprehensive Cancer Center

Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer

View More »

Washington : Washington Hospital Center

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Washington :

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

Washington : Sibley Memorial Hospital

Vaccine Therapy in Treating Patients With Breast Cancer

Fort Lauderdale : Holy Cross Hospital

ECOG E5508

Fort Lauderdale : Holy Cross Hospital

M12-895

Fort Lauderdale : Holy Cross Hospital

Nipple Sparing

Fort Lauderdale : Holy Cross Hospital Updated

NOLAN Study

Fort Lauderdale : Holy Cross Hospital

NSABP B-49

Fort Lauderdale : Holy Cross Hospital

PRESENT

Fort Lauderdale : Holy Cross Hospital

SWOG S1007

Fort Lauderdale : Holy Cross Hospital Updated

VINE Study

View More »

Additional Locations :

An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)

Boca Raton :

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

Clearwater : Morton Plant Mease Health Care

MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I

Coral Springs : Mary Beth Tomaselli

Randomized Study of Combination Chemotherapy With or Without Focused Microwave Thermotherapy Before Surgery in Treating Women With Large Breast Cancer Tumors

Fort Lauderdale : Broward General Medical Center Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Fort Lauderdale : Research Site Updated

Video Impact on Neulasta Education

Fort Myers : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Fort Myers : Updated

A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function

Fort Myers : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Fort Myers : 21st Century Oncology

NBRST: Prospective Neo-adjuvant REGISTRY Trial

Fort Myers :

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

Fort Myers : Florida Cancer Specialists

Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer

Hollywood : Updated

A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer

Hollywood : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Hollywood : Memorial Cancer Institute Breast Cancer Center

PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

Hollywood : Memorial Regional Cancer Center MRCC Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Jacksonville : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Jacksonville : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Jacksonville : Baptist Medical Center South

Patient Controlled Tissue Expansion for Breast Reconstruction

Jacksonville : Baptist Cancer Institute - Jacksonville

Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer

Jacksonville : Florida Oncology Associates Orange Park Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Jacksonville :

Study Evaluating the Safety and Efficacy of Onartuzumab (Metmab) And/Or Bevacizumab in Combination With Paclitaxel in Patients With Metastatic, Triple Negative Breast Cancer

Jacksonville :

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

Lake Worth : The Breast Institute at JFK Medical Center

NBRST: Prospective Neo-adjuvant REGISTRY Trial

Lake Worth : Cancer Center of South Florida Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Lakeland : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Miami : Updated

A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer

Miami : Updated

A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer

Miami : Baptist Health South Florida

NBRST: Prospective Neo-adjuvant REGISTRY Trial

Miami : University of Miami, Sylvester Comprehensive Cancer Center

PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

Miami : University of Miami

Phase 2 Trial of AEZS-108 in Chemotherapy Refractory in Triple Negative Breast Cancer

Miami : University of Miami Univ Miami 2 Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Miami Beach : CCOP - Mount Sinai Medical Center

Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer

New Port Richey : Pasco Hernando Oncology

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Ocala : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Orlando : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Orlando : MD Anderson Cancer Center - Orlando MD Orlando Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Pembroke Pines : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Pensacola : Sacred Heart Medical Oncology

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Pensacola : Sacred Heart Cancer Center at Sacred Heart Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Plantation : Updated

A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer

Plantation : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Plantation : Florida Cancer Research Institute Updated

Phase 2 Study of the Monoclonal Antibody MGAH22(Margetuximab)in Patients With Relapsed or Refractory Advanced Breast Cancer

Port St. Lucie : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Sarasota : Sarah Cannon Research Institute

A Study of Oral Rucaparib in Patients With gBRCA Mutation Breast or Ovarian Cancer, or Other Solid Tumor

Sarasota :

Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer

Sarasota : Florida Cancer Specialists

Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer

Savannah : Center for Breast Care

NBRST: Prospective Neo-adjuvant REGISTRY Trial

St. Petersburg : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

St. Petersburg :

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

Stuart : Martin Memorial Health Systems, Stuart - Robert & Carol Weissman Cancer Center

Adjunctive Efficacy Study Of The SoftScan® Optical Breast Imaging System

Tampa : H. Lee Moffitt Cancer Center and Research Institute

A Phase I Dose Escalation Study of Eribulin Plus Weekly Carboplatin for Metastatic Breast Patients

Tampa : H. Lee Moffitt Cancer Center/University of South Florida SC

A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation

Tampa : University of South Florida Breast Cancer Program

MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I

Tampa : H. Lee Moffitt Cancer Center and Research Institute at University of South Florida

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Titusville : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Titusville : Space Coast Medical Associates

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

West Palm Beach : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

West Palm Beach : Updated

Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

Savannah : Memorial University Medical Center

CCCWFU 97609: Impact of Genomics and Exposures on Disparities in Breast Cancer Radiosensitivity.

Savannah : Memorial University Medical Center

NSABP B-43: A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma in Situ Resected by Lumpectomy.

Savannah : Memorial University Medical Center

NSABP B-47: A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative Her2-Low Invasive Breast Cancer

Savannah : Memorial University Medical Center

NSABP B-49: A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer

Savannah : Memorial University Medical Center

RTOG 1005: A Phase III Trial of Accelerated Whole Breast Irradiation with Hypo-fractionation Plus Concurrent Boost versus Standard Whole Breast Irradiation Plus Sequential Boost for Early-Stage Breast Cancer

Savannah : Memorial University Medical Center

SWOG S0927: A Randomized Placebo-Controlled Trial of Omega-3 Fatty Acid for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain and Stiffness in Women with Early Stage Breast Cancer, Phase III

Savannah : Memorial University Medical Center

SWOG S1007: A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER-2 Negative Breast Cancer with Recurrence Score (RS) of 25 or Less

View More »

Additional Locations :

An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)

Albany : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Albany : Phoebe Putney Memorial Hospital

Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer

Atlanta : Synta Pharmaceuticals Investigative Site

A Phase 2 Study Evaluating Ganetespib in Women With Metastatic HER2+ or Triple Negative Breast Cancer

Atlanta : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Atlanta : Updated

A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer

Atlanta : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Atlanta : Emory University Healthcare

Collection of FUJIFILM's 3Dimensional Mammograms

Atlanta : Emory University Winship Cancer Institute

Exemestane or Docetaxel-cytoxan in Low Recurrence Score Cancers

Atlanta : Emory University

Neoadjuvant Trial of Eribulin Followed by Dose Dense Doxorubicin and Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer

Atlanta : Emory University Winship Cancer Institute Updated

Preoperative Clinical Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Triple Negative (ER-, PR-, Her2-)Early Stage Breast Cancer

Atlanta : Emory University Winship Cancer Institute

Randomized Phase II Trial of Trastuzumab or EVEROLIMUS in Hormone-refractory Metastatic Breast Cancer

Atlanta : Emory University Winship Cancer Institute

Re-expression of ER in Triple Negative Breast Cancers

Atlanta : Piedmont Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Atlanta : Saint Joseph's Hospital of Atlanta

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Atlanta : CCOP - Atlanta Regional

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Atlanta : Northside Hospital Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Atlanta : Emory University Winship Cancer Institute

Trial Using Docetaxel Cytoxan in Breast Cancers With High Recurrence Scores

Austell : WellStar Cobb Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Carrolton : Updated

A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer

Columbus : John B. Amos Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Decatur : Dekalb Medical

NBRST: Prospective Neo-adjuvant REGISTRY Trial

Decatur : Georgia Cancer Specialists Georgia Cancer Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Decatur : Charles B. Eberhart Cancer Center at DeKalb Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Fayetteville : Piedmont Fayette Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Gainesville : Northeast Georgia Medical Center

NBRST: Prospective Neo-adjuvant REGISTRY Trial

Gainesville : Northeast Georgia Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Lawrenceville : Suburban Hematology-Oncology

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Lawrenceville : Gwinnett Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Marietta : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Marietta : Updated

A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer

Marietta : Northwest Georgia Oncology Center NW Georgia Onc

A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation

Marietta : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Marietta : Advanced Breast Care

NBRST: Prospective Neo-adjuvant REGISTRY Trial

Marietta : Kennestone Cancer Center at Wellstar Kennestone Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Marietta :

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

Riverdale : Southern Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Rome : Harbin Clinic Cancer Center - Medical Oncology

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Savannah : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Savannah : Curtis and Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Valdosta : Pearlman Comprehensive Cancer Center at South Georgia Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Additional Locations :

An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)

Aiea : Kapiolani Medical Center at Pali Momi

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Honolulu : Straub Clinic and Hospital, Incorporated

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Honolulu : OnCare Hawaii, Incorporated - Lusitana

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Honolulu : Cancer Research Center of Hawaii

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

View More »

Honolulu : Tripler Army Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Honolulu : OnCare Hawaii, Incorporated - Kuakini

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Honolulu : Queen's Cancer Institute at Queen's Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Honolulu : Kapiolani Medical Center for Women and Children

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Honolulu : Hawaii Medical Center - East

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Honolulu : University of Hawaii Cancer Center

Vaccine Therapy in Treating Patients With Breast Cancer

Lihue : Kauai Medical Clinic

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Wailuku : Pacific Cancer Institute - Maui

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Wailuku : Maui Memorial Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Boise : Mountain States Tumor Institute at St. Luke's Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Boise : Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Fruitland : Saint Luke's Mountain States Tumor Institute - Fruitland

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Lewiston : St. Joseph Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Many locations :

An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)

View More »

Meridian : Mountain States Tumor Institute - Meridian

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Nampa : Saint Luke's Mountain States Tumor Institute

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Post Falls : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Post Falls : Kootenai Cancer Center

Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer

Twin Falls : Mountain States Tumor Institute at St. Luke's

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Chicago : Northwestern University

Dose finding and tolerability study of alpha-lipoic acid in patients at risk for paclitaxel induced peripheral neuropathy

Elgin : Sherman Health

ECOG E2108 Phase III Randomized Study of Early Local Therapy Comprising Surgery Versus Standard Palliative Therapy for the Intact Primary Tumor in Patients With Stage IV Breast Cancer

Elgin : Sherman Health

ECOG E3108 Phase II Prospective Study of CYP2D6 Activity in Patients With Metastatic or Recurrent Breast Cancer Treated With Tamoxifen Citrate

Elgin : Sherman Health

NSABP B-47 Phase III Randomized Study of Adjuvant Chemotherapy With Versus Without Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer

Elgin : Sherman Health

NSABP B-49 Phase III Study of Docetaxel and Cyclophosphamide Versus Anthracycline-Based Chemotherapy Regimens in Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer

Elgin : Sherman Health

NSABP DMP-1 A Study to Evaluate Different Decision-Making Approaches Used by Women Known to be at Increased Risk for Breast Cancer

Elgin : Sherman Health

NSABP MA.32 Ancillary Study of Biobehavioral Mechanisms of Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin Hydrochloride Versus Placebo on NCIC-CTG-MA.32

Elgin : Sherman Health

RTOG 1005 Phase III Randomized Study of Accelerated Hypofractionated Whole-Breast Irradiation and Concurrent Boost Versus Standard Whole-Breast Irradiation and Sequential Boost in Patients With Early-Stage Breast Cancer After Lumpectomy

Elgin : Sherman Health

SWOG S0800 Phase II Randomized Study of Neoadjuvant Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Doxorubicin Hydrochloride, Cyclophosphamide, and Pegfilgrastim With Versus Without Bevacizumab in Women With HER2/neu-Negative Inflammatory or Locally Advanced Breast Cancer

Elgin : Sherman Health

SWOG S1007 Phase III Randomized Study of Standard Adjuvant Endocrine Therapy With Versus Without Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive, and HER2-Negative Breast Cancer

Elgin : Sherman Health

SWOG S1105 Randomized Study of Text-Messaging Intervention in Reducing Early Discontinuation of Adjuvant Aromatase Inhibitor Therapy in Women With Stage I, II, or III Breast Cancer

Elk Grove Village : Alexian Brothers Hospital Network

A multicenter, open-label, randomized trial to evaluate the anti-cancer effects of zoledronic acid and circulating tumor cell measurements in patients with HER2-negative metastatic breast cancer without bone metastasis

Elk Grove Village : Alexian Brothers Hospital Network

A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer

Elk Grove Village : Alexian Brothers Hospital Network

A randomized study to prevent lymphedema in women treated for breast cancer

Elk Grove Village : Alexian Brothers Hospital Network

NSABP PROTOCOL B-41 A Randomized Phase III Trial of Neoadjuvant Therapy for Patients with Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered with Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response

Elk Grove Village : Alexian Brothers Hospital Network

NSABP PROTOCOL B-43 A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy

View More »

Additional Locations :

An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)

Additional Locations : Cancer Care and Hematology Specialists of Chicagoland Niles Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Alton : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Aurora : Rush-Copley Cancer Care Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Bloomingdale : Advanced Breast Care Specialists

NBRST: Prospective Neo-adjuvant REGISTRY Trial

Carbondale : Memorial Hospital of Carbondale

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Chicago : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Chicago : GSK Investigational Site Updated

ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D

Chicago : University of Chicago

Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy

Chicago : Northwestern University

Phase 1/2 Study of ThermoDox With Approved Hyperthermia in Treatment of Breast Cancer Recurrence at the Chest Wall

Chicago : Advocate Illinois MasonicMedical Cent/Creticos Cancer Center Dept. of Creticos Cancer Cente Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Chicago : Vanguard Health Chicago Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Chicago : John H. Stroger, Jr. Hospital of Cook County

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Chicago : Louis A. Weiss Memorial Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Chicago : University of Chicago Updated

Using A Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy

Chicago : Northwestern University Updated

Using A Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy

Decatur : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Decatur : Decatur Memorial Hospital Cancer Care Institute

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Elgin : Sherman Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Elk Grove Village : University Surgical Consultants

NBRST: Prospective Neo-adjuvant REGISTRY Trial

Evanston : Evanston Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Geneva : Delnor Hospital - Geneva

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Harvey : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Hines : Veterans Affairs Medical Center - Hines

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Joliet :

A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Patients With Locally Recurrent or Metastatic Breast Cancer

Joliet : Updated

Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

Joliet :

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

Maywood : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Maywood : Cardinal Bernardin Cancer Center at Loyola University Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Moline :

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Moline : Trinity Cancer Center at Trinity Medical Center - 7th Street Campus

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Mount Vernon : Good Samaritan Regional Health Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Naperville : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Naperville : Edward Cancer Center

Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer

Normal : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Park Ridge : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Park Ridge : Advocate Lutheran General Hospital

NBRST: Prospective Neo-adjuvant REGISTRY Trial

Peoria : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Peoria :

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

Peoria : Research Site Updated

Video Impact on Neulasta Education

Plainfield : Edward Cancer Center Plainfield

Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer

River Forest : West Suburban Center for Cancer Care

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Skokie : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Springfield : Regional Cancer Center at Memorial Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Urbana : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Urbana : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Urbana : Carle Foundation Hospital

Real Time Optical Coherence Tomography (OCT) of Human Tissue

Urbana : CCOP - Carle Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Warrenville : Central Dupage Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Yorkville : Yorkville Family Practice

Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer

Anderson : Community Clinical Research Center

A Phase II, Randomized, Multi-Centre, Open-Label, Active-Controlled, Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

View More »

Additional Locations :

An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)

Anderson : Community Hospital of Anderson

Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

Beech Grove : St. Francis Hospital and Health Centers - Beech Grove Campus

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Elkhart : Elkhart Clinic, LLC

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Elkhart : Elkhart General Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Elkhart : Michiana Hematology-Oncology, PC - Elkhart

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Evansville : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Evansville : Updated

Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

Evansville : Research Institute of Deaconess Clinic

Study of 0.1% Uracil Ointment (1UO) Ointment for the Prevention of Hand-Foot Syndrome

Fort Wayne : Fort Wayne Oncology & Hematology, Inc

PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

Goshen : IU Health Goshen Cancer Center

Ph I Dose Escalation Study of Antibody-drug Conjugate IMMU-132 in Patients With Advanced Epithelial Cancers

Indianapolis : Indiana Unversity Cancer Center

Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise After Preoperative Chemotherapy for Breast Cancer

Indianapolis : Indiana University

Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy

Indianapolis : Indiana University Melvin and Bren Simon Cancer Center

PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

Indianapolis : Community Regional Cancer Center

PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

Indianapolis : Indiana University Updated

Phase 2 Study of the Monoclonal Antibody MGAH22(Margetuximab)in Patients With Relapsed or Refractory Advanced Breast Cancer

Indianapolis : St. Vincent Hospital and Health Care Center

Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer

Indianapolis : University of Indiana Updated

Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer

Kokomo : Howard Community Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

La Porte : Center for Cancer Therapy at LaPorte Hospital and Health Services

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Lafayette : Horizon Oncology Research, Inc./IU Health Arnett

PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

Michigan City : Saint Anthony Memorial Health Centers

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Mishawaka : Michiana Hematology-Oncology, PC - South Bend

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Mishawaka : Saint Joseph Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Munster : Monroe Medical Associates

PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

New Albany : Cancer Care Center

Study of 0.1% Uracil Ointment (1UO) Ointment for the Prevention of Hand-Foot Syndrome

Plymouth : Michiana Hematology Oncology PC - Plymouth

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Richmond : Reid Hospital & Health Care Services

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

South Bend : Northern Indiana Cancer Research

NBRST: Prospective Neo-adjuvant REGISTRY Trial

South Bend : Northern Indiana Cancer Research Consortium

PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

South Bend : Memorial Hospital of South Bend

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

South Bend : CCOP - Northern Indiana CR Consortium

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Westville : Michiana Hematology Oncology PC - La Porte

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Ames : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Ames : McFarland Clinic, PC

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Bettendorf :

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Cedar Rapids : Cedar Rapids Oncology Associates

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Cedar Rapids : Mercy Regional Cancer Center at Mercy Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

View More »

Clive : Medical Oncology and Hematology Associates - West Des Moines

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Davenport : Genesis Regional Cancer Center at Genesis Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Des Moines : Medical Oncology and Hematology Associates at Mercy Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Des Moines : Medical Oncology and Hematology Associates at John Stoddard Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Des Moines : John Stoddard Cancer Center at Iowa Methodist Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Des Moines : Mercy Cancer Center at Mercy Medical Center - Des Moines

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Des Moines : John Stoddard Cancer Center at Iowa Lutheran Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Des Moines : CCOP - Iowa Oncology Research Association

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Dubuque : Medical Associates Clinic, PC

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Iowa City : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Many locations :

An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)

Mason City : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Mason City : Mercy Cancer Center at Mercy Medical Center - North Iowa

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Mason City : Research Site Updated

Video Impact on Neulasta Education

Sioux City : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Sioux City : Siouxland Hematology-Oncology Associates LLP

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Sioux City : Mercy Medical Center - Sioux City

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Sioux City : Siouxland Hematology-Oncology Associates, LLP

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Sioux City : St. Luke's Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Additional Locations :

An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)

Chanute : Cancer Center of Kansas, PA - Chanute

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Dodge City : Cancer Center of Kansas, PA - Dodge City

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

El Dorado : Cancer Center of Kansas, PA - El Dorado

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Fort Scott : Cancer Center of Kansas - Fort Scott

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

View More »

Hays : Hays Medical Center Updated

Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression

Independence : Cancer Center of Kansas-Independence

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Kansas City : University of Kansas Medical Center Cancer Center Updated

Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression

Kansas City : University of Kansas Medical Center

Radiofrequency Ablation After Breast Lumpectomy (ABLATE)

Kansas City : University of Kansas Medical Center

Study of Breast Cancer Prevention by Letrozole in High Risk Women

Kingman : Cancer Center of Kansas, PA - Kingman

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Lawrence : Lawrence Memorial Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Liberal : Cancer Center of Kansas, PA - Liberal

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

McPherson : Cancer Center of Kansas, PA - McPherson

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Newton : Cancer Center of Kansas, PA - Newton

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Overland Park : Menorah Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Overland Park : Saint Luke's Hospital - South

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Overland Park : Kansas City Cancer Centers

Study of 0.1% Uracil Ointment (1UO) Ointment for the Prevention of Hand-Foot Syndrome

Parsons : Cancer Center of Kansas, PA - Parsons

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Prairie Village : CCOP - Kansas City

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Pratt : Cancer Center of Kansas, PA - Pratt

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Salina : Cancer Center of Kansas, PA - Salina

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Salina : Tammy Walker Cancer Center at Salina Regional Health Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Topeka : Cotton-O'Neil Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Wellington : Cancer Center of Kansas, PA - Wellington

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Westwood : The University of Kansas Cancer Center

Excision Followed by Radiofrequency Ablation for Breast Cancer

Wichita : Updated

A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer

Wichita : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Wichita : Cancer Center of Kansas

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Wichita : Cancer Center of Kansas CCK Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Wichita : Cancer Center of Kansas, PA - Medical Arts Tower

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Wichita : Associates in Womens Health, PA - North Review

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Wichita : Cancer Center of Kansas, PA - Wichita

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Wichita : Via Christi Cancer Center at Via Christi Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Wichita : CCOP - Wichita

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Wichita :

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

Winfield : Cancer Center of Kansas, PA - Winfield

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Additional Locations :

An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)

Hazard :

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Hazard : Kentucky Lung Clinic & Kentucky Sleep Clinic

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Lexington : University of Kentucky Medical Center

Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer

Louisville : Norton Healthcare, Inc.

A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation

View More »

Louisville : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Louisville : Updated

Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

Mount Sterling : Sandoz Investigational Site

Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim

Additional Locations :

An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)

Alexandria : Cabrini Center for Cancer Care

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Baton Rouge : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Baton Rouge : Ochsner Health Center - Bluebonnet

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Covington : Ochsner Health Center - Covington

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

View More »

Lafayette : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Marrero :

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Marrero : Updated

A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer

Metairie :

A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Patients With Locally Recurrent or Metastatic Breast Cancer

Monroe : Louisiana State University Health Sciences Center - Monroe

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

New Orleans : CCOP - Ochsner

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

New Orleans : Ochsner Cancer Institute at Ochsner Clinic Foundation

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Shreveport : Highland Clinic

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Shreveport : Feist-Weiller Cancer Center at Louisiana State University Health Sciences

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Additional Locations :

An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)

Bangor : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Portland : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Scarborough : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Additional Locations :

An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)

Baltimore : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Baltimore : Updated

A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer

Baltimore : Johns Hopkins Hospital

Computed Optical Margin Assessment for Breast Cancer Surgery

Baltimore : Greenbaum Cancer Center

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

View More »

Baltimore : Johns Hopkins

Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy

Baltimore : Mercy Medical Center Mercy Medical SC Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Baltimore : Sidney Kimmel Comprehensive Cancer Center/Johns Hopkins Med. Sidney/John Hopkins Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Baltimore : MedStar Good Samaritan Hospital Cancer Center

Vaccine Therapy in Treating Patients With Breast Cancer

Baltimore : MedStar Union Memorial Hospital

Vaccine Therapy in Treating Patients With Breast Cancer

Bethesda : Updated

A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer

Bethesda : Center for Cancer & Blood Disorders

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Bethesda : Walter Reed National Military Medical Center

Vaccine Therapy in Treating Patients With Breast Cancer

Cumberland : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Elkton : Union Hospital of Cecil County

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Frederick : Frederick Memorial Hospital Fred. Mem. Hosp. Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Lanham : Signature Breast Care

NBRST: Prospective Neo-adjuvant REGISTRY Trial

Rockville : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Rockville : Associates in Oncology/Hematology, P.C. SC Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Silver Spring : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Westminster : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Additional Locations :

An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)

Boston : Synta Pharmaceuticals Investigative Site

A Phase 2 Study Evaluating Ganetespib in Women With Metastatic HER2+ or Triple Negative Breast Cancer

Boston : Massachusetts General Hospital Updated

A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer

Boston : Dana-Farber Cancer Institute

A Study of Oral Rucaparib in Patients With gBRCA Mutation Breast or Ovarian Cancer, or Other Solid Tumor

Boston : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

View More »

Boston : Updated

A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer

Boston : Faulkner Hospital

Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise After Preoperative Chemotherapy for Breast Cancer

Boston : Dana-Farber Cancer Institute

Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise After Preoperative Chemotherapy for Breast Cancer

Boston : Dana Farber Cancer Institute

Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer

Boston : Beth Israel Deaconess Medical Center

Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer

Boston : Massachusetts General Hospital

Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer

Boston : Dana Farber Cancer Institute

Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy

Boston : Dana-Farber Cancer Institute

Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer

Boston : Dana-Farber at Faulkner Hospital

Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer

Boston : Beth Israel Deaconess Medical Center

Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer

Boston : Beth Israel Deaconess Medical Center

Patient Controlled Tissue Expansion for Breast Reconstruction

Boston : Faulkner Hospital

Patient Controlled Tissue Expansion for Breast Reconstruction

Boston : Massachusetts General Hospital

Patient Controlled Tissue Expansion for Breast Reconstruction

Boston : Tufts Cancer Center Updated

Phase 2 Study of the Monoclonal Antibody MGAH22(Margetuximab)in Patients With Relapsed or Refractory Advanced Breast Cancer

Boston : Massachusetts General Hospital SC Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Boston : Updated

Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

Boston : Dana-Farber Cancer Institute

Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer

Boston : Dana-Farber at Faulkner Hospital

Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer

Boston : Massachusetts General Hospital

Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer

Boston : Dana Farber Cancer Center Updated

Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer

Boston :

Study Evaluating the Safety and Efficacy of Onartuzumab (Metmab) And/Or Bevacizumab in Combination With Paclitaxel in Patients With Metastatic, Triple Negative Breast Cancer

Boston :

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

Boston : Dana-Farber Cancer Institute

Trastuzumab and Vinorelbine in Advanced Breast Cancer

Boston : Beth Israel Deaconess Medical Center

Trastuzumab and Vinorelbine in Advanced Breast Cancer

Boston : Dana-Farber Cancer Institute at Faulkner Hospital

Trastuzumab and Vinorelbine in Advanced Breast Cancer

Boston : Massachusetts General Hospital

Trastuzumab and Vinorelbine in Advanced Breast Cancer

Boston : Massachusetts General Hospital

Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors

Fairhaven : Research Site Updated

Video Impact on Neulasta Education

Methuen : Caritas Holy Family Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Milford : Dana-Farber/Brigham and Women's Cancer Center at Milford Regional Medical Center

Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise After Preoperative Chemotherapy for Breast Cancer

Pittsfield : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Worcester : University of Massachusetts Memorial Medical Center

Patient Controlled Tissue Expansion for Breast Reconstruction

Additional Locations :

An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)

Adrian : Hickman Cancer Center at Bixby Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Ann Arbor : CCOP - Michigan Cancer Research Consortium

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Ann Arbor : Saint Joseph Mercy Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Ann Arbor : University of Michigan Comprehensive Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

View More »

Battle Creek : Battle Creek Health System Cancer Care Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Bay City : Bay Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Big Rapids : Mecosta County Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Dearborn : Oakwood Cancer Center at Oakwood Hospital and Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Detroit : Karmanos Cancer Institute

A Study of Oral Rucaparib in Patients With gBRCA Mutation Breast or Ovarian Cancer, or Other Solid Tumor

Detroit : Updated

A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function

Detroit : Henry Ford Health System

Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer

Detroit : Sandoz Investigational Site

Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim

Detroit : Josephine Ford Cancer Center at Henry Ford Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Detroit : Karmanos Cancer Center Updated

Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer

Detroit :

Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer

Escanaba : Green Bay Oncology, Limited - Escanaba

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Flint : Hurley Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Flint : Genesys Hurley Cancer Institute

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Flint : Singh and Arora Hematology Oncology, PC

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Flint : McLaren Cancer Institute

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Grand Rapids : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Grand Rapids : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Grand Rapids : CCOP - Grand Rapids

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Grand Rapids : Butterworth Hospital at Spectrum Health

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Grand Rapids : Lacks Cancer Center at Saint Mary's Health Care

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Grosse Pointe Woods : Van Elslander Cancer Center at St. John Hospital and Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Iron Mountain : Dickinson County Healthcare System

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Jackson : Foote Memorial Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Kalamazoo : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Kalamazoo : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Kalamazoo : West Michigan Cancer Center

Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer

Kalamazoo : Borgess Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Kalamazoo : Bronson Methodist Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Kalamazoo : West Michigan Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Lansing : Breslin Cancer Center at Ingham Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Lansing : Sparrow Regional Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Lapeer : Great Lakes Cancer Institute - Lapeer Campus

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Livonia : St. Mary Mercy Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Monroe : Community Cancer Center of Monroe

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Monroe : Mercy Memorial Hospital - Monroe

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Mount Clemens : Clemens Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Muskegon : Mercy General Health Partners

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Petoskey : Northern Michigan Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Pontiac : St. Joseph Mercy Oakland

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Port Huron : Mercy Regional Cancer Center at Mercy Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Reed City : Spectrum Health Reed City Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Royal Oak : William Beaumont Hospital - Royal Oak Campus

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Royal Oak : William Beaumont Hospital

Safety Study for Short-course Accelerated, Hypofractionated Partial Breast Radiotherapy (APBI) in Women With Early Stage Breast Cancer Using the Contura MLB

Saginaw : Seton Cancer Institute at Saint Mary's - Saginaw

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Southfield : Providence Hospital - Southfield

Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer

Southfield : Providence Cancer Institute at Providence Hospital - Southfield Campus

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

St. Joseph : Lakeland Regional Cancer Care Center - St. Joseph

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

St. Joseph : Lakeside Cancer Specialists, PLLC

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Traverse City : Munson Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Warren : St. John Macomb Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Wyoming : Metro Health Cancer Care

PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

Additional Locations :

An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)

Brainerd : St. Joseph's Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Burnsville : Fairview Ridges Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Coon Rapids : Mercy and Unity Cancer Center at Mercy Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Duluth : Miller - Dwan Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

View More »

Duluth : Duluth Clinic Cancer Center - Duluth

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Duluth : CCOP - Duluth

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Edina : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Edina : Fairview Southdale Medical Oncology Clinic Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Edina : Fairview Southdale Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Fridley : Mercy and Unity Cancer Center at Unity Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Hutchinson : Hutchinson Area Health Care

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Maplewood : Minnesota Oncology - Maplewood

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Maplewood : HealthEast Cancer Care at St. John's Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Minneapolis : Hennepin County Medical Center - Minneapolis

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Minneapolis : Virginia Piper Cancer Institute at Abbott - Northwestern Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

New Ulm : New Ulm Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Robbinsdale : Humphrey Cancer Center at North Memorial Outpatient Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Saint Paul : United Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Shakopee : St. Francis Cancer Center at St. Francis Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

St. Cloud : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

St. Louis Park : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

St. Louis Park : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

St. Louis Park : CCOP - Metro-Minnesota

Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer

St. Louis Park : CCOP - Metro-Minnesota

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

St. Louis Park : Park Nicollet Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

St. Paul : Regions Hospital Cancer Care Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Stillwater : Lakeview Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Waconia : Ridgeview Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Willmar : Willmar Cancer Center at Rice Memorial Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Woodbury : Minnesota Oncology - Woodbury

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Additional Locations :

An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)

Jackson : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Jackson : Updated

Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

Jackson : Veterans Affairs Medical Center - Jackson

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Jackson : University of Mississippi Cancer Clinic

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

View More »

Pascagoula : Regional Cancer Center at Singing River Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Tupelo : Hematology and Oncology Association at Bridgepoint Hem Onc Bridgeport Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Additional Locations :

An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)

Cape Girardeau : Southeast Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Cape Girardeau : Saint Francis Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Columbia : University of Missouri-Ellis Fischel

Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer

Jefferson City : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

View More »

Jefferson City : Goldschmidt Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Jefferson City : Research Site Updated

Video Impact on Neulasta Education

Kansas City : St Lukes Cancer Center

NBRST: Prospective Neo-adjuvant REGISTRY Trial

Kansas City : Research Medical Center Reseach Med Ctr Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Kansas City : Research Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Kansas City : Veterans Affairs Medical Center - Kansas City

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Kansas City : North Kansas City Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Kansas City : Heartland Hematology Oncology Associates, Incorporated

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Kansas City : Saint Luke's Cancer Institute at Saint Luke's Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Lee's Summit : Saint Luke's East - Lee's Summit

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Liberty : Parvin Radiation Oncology

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Springfield : Updated

Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

St. Joseph : Heartland Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

St. Joseph : Saint Joseph Oncology, Incorporated

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

St. Louis : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

St. Louis : Updated

A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer

St. Louis : Washington University School Of Medicine-Siteman Cancer Ctr Was Univ School of Med

A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation

St. Louis : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

St. Louis : Christian Hospital

NBRST: Prospective Neo-adjuvant REGISTRY Trial

St. Louis : Siteman Cancer Center

PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

St. Louis : CCOP - St. Louis-Cape Girardeau

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

St. Louis : Christian Hospital Northeast Cancer Care Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

St. Louis : Midwest Hematology Oncology Group, Incorporated

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

St. Louis : Saint Louis University Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

St. Louis : Missouri Baptist Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

St. Louis : David C. Pratt Cancer Center at St. John's Mercy

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

St. Louis :

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

St. Louis : Bodyaesthetic Updated

Using A Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy

St. Louis : Research Site Updated

Video Impact on Neulasta Education

Billings :

A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Patients With Locally Recurrent or Metastatic Breast Cancer

Billings : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Billings : Billings Clinic - Downtown

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Billings : St. Vincent Healthcare Cancer Care Services

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Billings : CCOP - Montana Cancer Consortium

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

View More »

Billings : Hematology-Oncology Centers of the Northern Rockies - Billings

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Bozeman : Bozeman Deaconess Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Butte : St. James Healthcare Cancer Care

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Great Falls : Big Sky Oncology

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Great Falls : Sletten Cancer Institute at Benefis Healthcare

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Helena : St. Peter's Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Kalispell : Kalispell Medical Oncology at KRMC

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Kalispell : Kalispell Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Many locations :

An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)

Missoula : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Missoula : Montana Cancer Center at St. Patrick Hospital and Health Sciences Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Missoula : Montana Cancer Specialists at Montana Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Additional Locations :

An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)

Kearney : Good Samaritan Cancer Center at Good Samaritan Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Lincoln : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Lincoln : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Lincoln : Southeast Nebraska Oncology Cancer Center Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

View More »

Lincoln : Cancer Resource Center - Lincoln

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Omaha :

A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Patients With Locally Recurrent or Metastatic Breast Cancer

Omaha : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Omaha : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Omaha : Lakeside Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Omaha : Alegant Health Cancer Center at Bergan Mercy Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Omaha : CCOP - Missouri Valley Cancer Consortium

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Omaha : Immanuel Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Omaha : Creighton University Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Additional Locations :

An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)

Las Vegas : Compehensive Cancer Care of Nevada

NBRST: Prospective Neo-adjuvant REGISTRY Trial

Las Vegas : Comprehensive Cancer Centers of Nevada

PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

Las Vegas : University Medical Center of Southern Nevada

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Las Vegas : CCOP - Nevada Cancer Research Foundation

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

View More »

Las Vegas : Nevada Cancer Institute

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Syracuse : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Additional Locations :

An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)

Hooksett : New Hampshire Oncology-Hematology PA

Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer

Lebanon : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Lebanon : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Lebanon : Research Site

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

View More »

Portsmouth : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Portsmouth : Research Site Updated

Video Impact on Neulasta Education

Paramus : The Valley Hospital/Valley Health System

Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)

View More »

Additional Locations :

An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)

Basking Ridge : Memorial Sloan-Kettering at Basking Ridge

Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer

Basking Ridge :

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

Basking Ridge : Memorial Sloan-Kettering at Basking Ridge Updated

Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer

Berkeley Heights : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Brick : Meridian Health Systems Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Cherry Hill : The Center for Cancer & Hematologic Disease

PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

Denville : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Hackensack : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Hackensack :

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

Livingston : Saint Barnabas Medical Center

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Morristown : Updated

A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer

Morristown : Updated

A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer

Morristown : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Morristown : Research Site Updated

Video Impact on Neulasta Education

Mount Holly : Virtua Health Cancer Program

PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

New Brunswick : Cancer Institute of New Jersey

Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer

New Brunswick : Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School

Internal Radiation Therapy of the Breast in Treating Women With Early-Stage Breast Cancer

New Brunswick : Cancer Institute of New Jersey

Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer

New Brunswick : Cancer Institute of New Jersey

Safety Study for Short-course Accelerated, Hypofractionated Partial Breast Radiotherapy (APBI) in Women With Early Stage Breast Cancer Using the Contura MLB

Newark : UMDNJ University Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Paramus : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Paramus : The Valley Hospital / Luckow Pavillion Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Vineland : South Jersey Health Care

PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

Voorhees : Updated

A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer

Voorhees : Cancer Institute of New Jersey at Cooper - Voorhees

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Willingboro : Virtua Health

NBRST: Prospective Neo-adjuvant REGISTRY Trial

Additional Locations :

An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)

Albuquerque : Presbyterian Medical Group

PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

Albuquerque : University of New Mexico Cancer Care Alliance

PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

Albuquerque : Updated

Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

Albuquerque : Hematology Oncology Associates, PC

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

View More »

Albuquerque : University of New Mexico Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Albuquerque : Research Site Updated

Video Impact on Neulasta Education

Jamaica : Biomedical Research Alliance of New York

HER2-positive Locally Recurrent or Metastatic Breast Cancer

Lake Success : Biomedical Research Alliance of New York

Breast Cancer

View More »

Bronx : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Bronx : Updated

A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Patients With HER2-Positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-Directed Therapy (TH3RESA)

Bronx : Montefiore Medical Center

Trial for Locally Advanced Her2 Positive Breast Cancer Using Paclitaxel, Trastuzumab, Doxorubicin and Cyclophasmide on a Weekly Basis

Buffalo : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Commack : Memorial Sloan-Kettering Cancer Center @ Suffolk

Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer

Commack :

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

Commack : Memorial Sloan-Kettering Cancer Center @ Suffolk Updated

Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer

Cooperstown : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Cooperstown : Research Site Updated

Video Impact on Neulasta Education

Cortlandt Manor : Ashikari Breast Center

NBRST: Prospective Neo-adjuvant REGISTRY Trial

East Setauket : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

East Setauket :

Study Evaluating the Safety and Efficacy of Onartuzumab (Metmab) And/Or Bevacizumab in Combination With Paclitaxel in Patients With Metastatic, Triple Negative Breast Cancer

East Syracuse : CCOP - Hematology-Oncology Associates of Central New York

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Elmira : Falck Cancer Center at Arnot Ogden Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Great Neck : Arena Oncology Associates, PC

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Great Neck : Research Site

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

Great Neck : Aesthetic Plastic Surgery Updated

Using A Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy

Lake Success : Updated

A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer

Lake Success : Arena Oncology Associates, PC SC Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Lake Success : Updated

Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

Many locations :

An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)

New York : Synta Pharmaceuticals Investigative Site

A Phase 2 Study Evaluating Ganetespib in Women With Metastatic HER2+ or Triple Negative Breast Cancer

New York : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

New York : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

New York : Memorial Sloan Kettering Cancer Center

Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise After Preoperative Chemotherapy for Breast Cancer

New York : Memorial Sloan Kettering Cancer Center

Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer

New York : Memorial Sloan-Kettering Cancer Center Updated

Dasatinib In Combination With Weekly Paclitaxel For Patients With Metastatic Breast Carcinoma CA 180 194

New York : Columbia

Excision Followed by Radiofrequency Ablation for Breast Cancer

New York : Memorial Sloan Kettering Cancer Center

Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer

New York : Columbia University

Patient Controlled Tissue Expansion for Breast Reconstruction

New York : Weill Cornell/New York Presbyterian Hospital

Ph I Dose Escalation Study of Antibody-drug Conjugate IMMU-132 in Patients With Advanced Epithelial Cancers

New York : Research Site

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

New York :

Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer

New York : Memorial Sloan-Kettering Cancer Center

Safety Study of Topical Compound 31543 (Calcitriol, USP) in Patients Receiving Chemotherapy for Breast Cancer

New York : Columbia University

Study of Erlotinib and Metformin in Triple Negative Breast Cancer

New York :

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

New York : Memorial Sloan Kettering Cancer Center Updated

Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer

New York : Weill Cornell Breast Center Updated

Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer

New York : Memorial Sloan-Kettering Cancer Center

Tobacco Dependence in Breast Cancer Patients Scheduled for Mastectomy/Reconstructive Surgery Trial of Varenicline (Chantix)

New York : Memorial Sloan Kettering Cancer Center

Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors

New York : Memorial Sloan Kettering Cancer Center Updated

Whole Brain Radiotherapy (WBRT) With Sorafenib for Breast Cancer Brain Metastases (BCBM)

Oceanside : South Nassau Communities Hospital

Patient Controlled Tissue Expansion for Breast Reconstruction

Rochester : Elizabeth Wende Breast Care

Cone Beam Computed Tomography for Breast Imaging

Rochester : University of Rochester Medical Center Highland Breast Imaging Center

Koning Breast Computed Tomography Guided Neoadjuvant Treatment Monitoring

Rochester : James P. Wilmot Cancer Center at University of Rochester Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Rockville Centre : Memorial Sloan-Kettering at Mercy Medical Center

Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer

Rockville Centre :

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

Rockville Centre : Memorial Sloan-Kettering at Mercy Medical Center Updated

Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer

Sleepy Hollow : Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center

Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer

Sleepy Hollow :

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

Sleepy Hollow : Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center Updated

Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer

Stony Brook : University Hospital and Medical Center - SUNY Stony Brook

Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer

Troy : New York Oncology Hematology, P.C. Dept. of New York Oncology. PC

A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation

Additional Locations :

An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)

Asheboro : Research Site Updated

Video Impact on Neulasta Education

Asheville : HOPE a Women's Cancer Center

PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

Asheville : Mission Hospitals - Memorial Campus

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Chapel Hill : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

View More »

Charlotte : Updated

A Study of Trastuzumab Emtansine (T-DM1) in Combination With Docetaxel, and Potentially Pertuzumab, in Patients With Advanced Breast Cancer

Charlotte : Updated

A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)

Charlotte : Carolinas Medical Center/Levine Cancer Center

Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer

Charlotte : CCOP Carolinas HealthCare System

Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer

Charlotte : Presbyterian Health Care

Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer

Charlotte : Presbyterian Cancer Center at Presbyterian Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Concord : Updated

A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)

Concord : Northeast Oncology Associates

Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer

Durham : Synta Pharmaceuticals Investigative Site

A Phase 2 Study Evaluating Ganetespib in Women With Metastatic HER2+ or Triple Negative Breast Cancer

Durham : Updated

A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer

Durham : Duke University Medical Center

Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise After Preoperative Chemotherapy for Breast Cancer

Durham : Duke University

Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy

Durham : Duke University Medical Center

Patient Controlled Tissue Expansion for Breast Reconstruction

Durham : Duke University Medical Center

Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer

Durham : Updated

Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

Gastonia : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Goldsboro : Wayne Memorial Hospital, Incorporated

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Goldsboro : Research Site Updated

Video Impact on Neulasta Education

Greensboro : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Hendersonville : Pardee Memorial Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Hickory : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Monroe : Updated

A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)

Pinehurst : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Pinehurst : FirstHealth Moore Regional Community Hospital Comprehensive Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Raleigh : Tolnitch Surgical Associates

NBRST: Prospective Neo-adjuvant REGISTRY Trial

Rutherfordton : Rutherford Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Shelby : Updated

A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)

Statesville : Iredell Memorial Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Wilmington : MotHER Registry Coordinating Center

An Observational Study Of Pregnancy And Pregnancy Outcomes In Women With Breast Cancer Treated With Herceptin Or Perjeta In Combination With Herceptin During Pregnancy Or Within 6 Months Prior To Conception (MotHER)

Winston-Salem : Wake Forest University School of Medicine

Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer

Winston-Salem : Forsyth Regional Cancer Center

Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer

Winston-Salem : Forsyth Regional Cancer Center at Forsyth Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Winston-Salem : Wake Forest University Comprehensive Cancer Center

Vaccine Therapy in Treating Patients With Breast Cancer

Bismarck : St. Alexius Medical Center

A study of an investigational medication for treatment for patients who have or have had breast cancer. The investigational medication is being developed for use after completion of standard of care therapy for early stage breast cancer to potentially prevent recurrence of the cancer.

Bismarck : Legacy Pharma Research

Chemotherapy Induced Anemia in Patients with Metastatic Breast Cancer

View More »

Additional Locations :

An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)

Bismarck : Sandoz Investigational Site

Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim

Bismarck : Mid Dakota Clinic, P.C. Dept of Oncology Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Additional Locations :

An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)

Akron : McDowell Cancer Center at Akron General Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Bowling Green : Wood County Oncology Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Canton : Research Site Updated

Video Impact on Neulasta Education

Chillicothe : Adena Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

View More »

Cincinnati : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Cincinnati : Charles M. Barrett Cancer Center at University Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Cincinnati : Oncology Hematology Care, Inc.

Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer

Cleveland : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Cleveland : Seidman Cancer Center

PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

Cleveland : Case Western Reserve University/University Hospitals of Cleveland

Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer

Columbus : Synta Pharmaceuticals Investigative Site

A Phase 2 Study Evaluating Ganetespib in Women With Metastatic HER2+ or Triple Negative Breast Cancer

Columbus : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Columbus : Updated

A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer

Columbus : Ohio State Comprehensive Cancer Center/James Cancer Hospital SC-1

A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation

Columbus : Ohio State University

Agatolimod and Trastuzumab in Treating Patients With Locally Advanced or Metastatic Breast Cancer

Columbus : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Columbus : Mount Carmel Health - West Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Columbus : Doctors Hospital at Ohio Health

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Columbus : CCOP - Columbus

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Columbus : Grant Medical Center Cancer Care

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Columbus : Riverside Methodist Hospital Cancer Care

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Dayton : CCOP - Dayton

Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer

Dayton : Good Samaritan Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Dayton : David L. Rike Cancer Center at Miami Valley Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Dayton : Grandview Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Dayton : CCOP - Dayton

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Dayton : Samaritan North Cancer Care Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Delaware : Grady Memorial Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Elyria : Hematology Oncology Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Elyria : Community Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Findlay : Blanchard Valley Medical Associates

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Franklin : Middletown Regional Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Greenville : Wayne Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Kettering : CCOP - Dayton

Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer

Kettering : Charles F. Kettering Memorial Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Lancaster : Fairfield Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Lima : Lima Memorial Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Marietta : Strecker Cancer Center at Marietta Memorial Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Massillon : Research Site Updated

Video Impact on Neulasta Education

Maumee : Northwest Ohio Oncology Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Middletown : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Middletown : Research Site

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

Middletown : Signal Point Clinical Research Center

Study of 0.1% Uracil Ointment (1UO) Ointment for the Prevention of Hand-Foot Syndrome

Mount Vernon : Knox Community Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Newark : Licking Memorial Cancer Care Program at Licking Memorial Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Oregon : St. Charles Mercy Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Oregon : Toledo Clinic - Oregon

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Portsmouth : Southern Ohio Medical Center Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Springfield : Community Hospital of Springfield and Clark County

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Sylvania : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Sylvania : Flower Hospital Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Tiffin : Mercy Hospital of Tiffin

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Toledo : St. Vincent Mercy Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Toledo : Medical University of Ohio Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Toledo : Toledo Clinic, Incorporated - Main Clinic

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Toledo : CCOP - Toledo Community Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Toledo : Toledo Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Toledo : St. Anne Mercy Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Troy : UVMC Cancer Care Center at Upper Valley Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Wauseon : Fulton County Health Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

West Worthington : Hematology/Oncology Consultants Inc.

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Westerville : Mount Carmel St. Ann's Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Wright-Patterson Afb : United States Air Force Medical Center - Wright-Patterson

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Xenia : Ruth G. McMillan Cancer Center at Greene Memorial Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Zanesville : Genesis - Good Samaritan Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Additional Locations :

An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)

Oklahoma City : University of Oklahoma Health Sciences Center OUHSC 2

A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation

Oklahoma City : Dr. William Dooley

Randomized Study of Combination Chemotherapy With or Without Focused Microwave Thermotherapy Before Surgery in Treating Women With Large Breast Cancer Tumors

Oklahoma City : Peggy and Charles Stephenson Cancer Center

Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer

Tulsa : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

View More »

Tulsa : Southwestern Regional Medical Center

Phase 1/2 Study of ThermoDox With Approved Hyperthermia in Treatment of Breast Cancer Recurrence at the Chest Wall

Eugene : Clinical Trials of America, Inc

Women of 18 years or older with histologically proven breast cancer, eligible for neoadjuvant or adjuvant TAC chemotherapy

View More »

Additional Locations :

An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)

Bend : Research Site Updated

Video Impact on Neulasta Education

Clackamas : Clackamas Radiation Oncology Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Coos Bay : Bay Area Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Eugene : Sandoz Investigational Site

Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim

Grants Pass : Three Rivers Community Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Gresham : Legacy Mount Hood Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Medford : Providence Cancer Center at PMCC

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Medford : Dubs Cancer Center at Rogue Valley Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Milwaukie : Providence Milwaukie Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Newberg : Providence Newberg Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Oregon City : Willamette Falls Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Portland : Northwest Cancer Specialists Vancouver Loc

A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation

Portland : Updated

A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function

Portland : GSK Investigational Site Updated

ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D

Portland : Northwest Cancer Specialists Portland Loc Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Portland : Providence Cancer Center at Providence Portland Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Portland : Providence St. Vincent Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Portland : CCOP - Columbia River Oncology Program

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Portland : Legacy Good Samaritan Hospital & Comprehensive Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Tualatin : Legacy Meridian Park Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Additional Locations :

An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)

Allentown : Breast Care Specialists

NBRST: Prospective Neo-adjuvant REGISTRY Trial

Allentown : Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Bethlehem : St. Luke's Hospital and Health Network St Luke Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Dunmore : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

View More »

Harrisburg : Pinnacle Health Fox Chase Regional Cancer Center

PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

Hershey : Milton S Hershey Medical Center

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Hershey : Penn State Milton S. Hershey Medical Center

Trial of RAD001 in Triple Negative Metastatic Breast Cancer

Lancaster : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Philadelphia : Synta Pharmaceuticals Investigative Site

A Phase 2 Study Evaluating Ganetespib in Women With Metastatic HER2+ or Triple Negative Breast Cancer

Philadelphia : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Philadelphia : Updated

A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer

Philadelphia : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Philadelphia : Albert Einstein Medical Center

Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer

Philadelphia : Updated

Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

Philadelphia : Thomas Jefferson University, Dept of Radiology Updated

Quantitative Subharmonic Breast Imaging

Philadelphia : Albert Einstein Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Philadelphia :

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

Pittsburgh : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Pittsburgh : Updated

A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer

Pittsburgh : University of Pittsburgh Medical Center Cancer Center

Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise After Preoperative Chemotherapy for Breast Cancer

Pittsburgh : Allegheny General Hospital/Allegheny-Singer Research Institute

Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer

Pittsburgh : NSABP Foundation, Inc.

Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer

Pittsburgh : University of Pittsburgh

Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer

Pittsburgh : St. Clair Hospital

NBRST: Prospective Neo-adjuvant REGISTRY Trial

Pittsburgh : Allegheny Cancer Center at Allegheny General Hospital

Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer

Pittsburgh : NSABP Foundation, Inc.

Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer

Pittsburgh : University of Pittsburgh

Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer

Sayre : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Sayre : Guthrie Cancer Center

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Sellersville : Bux-Mont Oncology Hematology Associates (FCCC) at Grand View Hospital

PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

Willow Grove : Abington Hematology Oncology Associates, Inc Abington Hem Onc Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

York : Updated

A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)

York : York Hospital

Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer

Additional Locations :

An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)

Providence : Rhode Island Hospital

Breast Cancer Biomarker Sample Collection for the dtectDx Assay Verification

Additional Locations :

An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)

Anderson : AnMed Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Charleston : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Charleston : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Charleston : Cancer Specialists of Charleston

NBRST: Prospective Neo-adjuvant REGISTRY Trial

View More »

Charleston : The Breast Place

NBRST: Prospective Neo-adjuvant REGISTRY Trial

Charleston : Roper Hosp & Med Asso (Care Alliance Health)

Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer

Charleston : Charleston Hematology Oncology Association PA Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Charleston : Hollings Cancer Center at Medical University of South Carolina

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Charleston :

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

Columbia : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Columbia : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Easley : Cancer Centers of the Carolinas - Easley

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Greenville :

A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Patients With Locally Recurrent or Metastatic Breast Cancer

Greenville : Cancer Centers of the Carolinas

Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer

Greenville : Cancer Centers of the Carolinas - Grove Commons

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Greenville : Cancer Centers of the Carolinas - Faris Road

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Greenville : CCOP - Greenville

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Greenville : Bon Secours St. Francis Health System

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Greenville : Greenville Hospital Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Greenville : Cancer Centers of the Carolinas - Eastside

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Greenwood : Self Regional Cancer Center at Self Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Greer : Cancer Centers of the Carolinas - Greer Medical Oncology

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Greer : Cancer Centers of the Carolinas - Greer Radiation Oncology

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Murrells Inlet : Coastal Carolina Breast Center

NBRST: Prospective Neo-adjuvant REGISTRY Trial

Seneca : Cancer Centers of the Carolinas - Seneca

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Spartanburg : Spartanburg Regional Healthcare System

Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer

Spartanburg : CCOP - Upstate Carolina

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Spartanburg : Gibbs Regional Cancer Center at Spartanburg Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Spartanburg : Cancer Centers of the Carolinas - Spartanburg

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Sumter : Santee Hematology/Oncology

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Additional Locations :

An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)

Sioux Falls : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Sioux Falls : Avera Research Institute

Breast Cancer Biomarker Sample Collection for the dtectDx Assay Verification

Sioux Falls : Sanford Cancer Center at Sanford USD Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Additional Locations :

An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)

Bristol : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Bristol : Updated

Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

Bristol : Research Site Updated

Video Impact on Neulasta Education

Chattanooga : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

View More »

Chattanooga : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Chattanooga :

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

Chattanooga : Chattanooga Oncology Hematology Associates

Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer

Cookeville : Cookeville Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Germantown : Sandoz Investigational Site

Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim

Kingsport : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Knoxville : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Knoxville : Tennesee Cancer Specialists

NBRST: Prospective Neo-adjuvant REGISTRY Trial

Knoxville : Tennessee Cancer Specialists Center for Biomedical Research Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Memphis : The West Clinic

PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

Memphis : Updated

Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

Memphis :

Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer

Memphis :

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

Nashville : Sarah Cannon Research Institute

A Study of Oral Rucaparib in Patients With gBRCA Mutation Breast or Ovarian Cancer, or Other Solid Tumor

Nashville : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Nashville : Updated

A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function

Nashville : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Nashville : Vanderbilt-Ingram Cancer Center

Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise After Preoperative Chemotherapy for Breast Cancer

Nashville : Vanderbilt University Medical Center

Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy

Nashville : Nashville Breast Center

NBRST: Prospective Neo-adjuvant REGISTRY Trial

Nashville : Tennessee Oncology Updated

Phase 2 Study of the Monoclonal Antibody MGAH22(Margetuximab)in Patients With Relapsed or Refractory Advanced Breast Cancer

Nashville : Vanderbilt University Medical Center Vanderbilt - Thompson Ln Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Nashville :

Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer

Nashville : Sarah Cannon Research Institute

Safety Study of MGAH22 in HER2-positive Carcinomas

Nashville : Vanderbilt-Ingram Cancer Center

Study of ARN-810 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

Nashville :

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

Nashville : Sarah Cannon Research Institute

Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer

Nashville : Sarah Cannon Research Institute

Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors

Nashville : Tennessee Oncology, PLLC

Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer

Abilene : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Additional Locations :

An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)

Amarillo : Harrington Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Austin :

A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Patients With Locally Recurrent or Metastatic Breast Cancer

Bedford :

A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Patients With Locally Recurrent or Metastatic Breast Cancer

View More »

Bryan : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Dallas : Baylor College of Medicine SC

A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With LCL161 in Patients With Triple Negative Breast Cancer

Dallas : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Dallas : Texas Oncology, P.A. Central Austin CancerCenter(2)

A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation

Dallas : Baylor College of Medicine Baylor Texas Oncology

A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation

Dallas : Texas Health

NBRST: Prospective Neo-adjuvant REGISTRY Trial

Dallas : Dallas Surgical Group

NBRST: Prospective Neo-adjuvant REGISTRY Trial

Dallas : Texas Oncology, P.A. TX Onc - Southwest Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Dallas : Texas Oncology, P.A. TX Onc - Med City Dallas Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Dallas : Texas Oncology, P.A. TX Onc - Bedford Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Dallas : Texas Oncology, P.A. Midtown Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Dallas :

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

Dallas : UT Southwestern Updated

Using A Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy

Edinburg : McAllen Oncology

NBRST: Prospective Neo-adjuvant REGISTRY Trial

El Paso : Updated

Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

Fort Hood : Carl R. Darnall Army Medical Center

Vaccine Therapy in Treating Patients With Breast Cancer

Fort Sam Houston : Brooke Army Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Fort Sam Houston : San Antonio Army Medical Center

Vaccine Therapy in Treating Patients With Breast Cancer

Fort Worth :

A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Patients With Locally Recurrent or Metastatic Breast Cancer

Fort Worth : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Fort Worth :

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

Galveston : University of Texas Medical Branch

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Garland : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Houston : TOPS

A Comparison of Recall Rates Between Conventional 2d Mammography and 2d Plus 3d (Tomosynthesis) Mammography in a Screening Population

Houston : Synta Pharmaceutical Investigative Site

A Phase 2 Study Evaluating Ganetespib in Women With Metastatic HER2+ or Triple Negative Breast Cancer

Houston : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Houston : Updated

A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer

Houston : Updated

A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer

Houston : Baylor College of Medicine

Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer

Houston : U T M D Anderson Cancer Center

Dose-escalation Study of Oral CX-4945

Houston : Baylor College of Medicine Lester and Sue Smith Breast Center

Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy

Houston : UT MD Anderson Cancer Center

Genomic Testing for Primary Breast Cancer

Houston : East Houston General Surgery

NBRST: Prospective Neo-adjuvant REGISTRY Trial

Houston : The Methodist Hospital Cancer Center

Neo-Adjuvant Study in Triple Negative Breast Cancer Patients

Houston : UT MD Andreson Cancer Center

Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2

Houston : UT MD Anderson Cancer Center

Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer

Houston : MD Anderson Cancer Center

Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer

Houston : Oncology Consultants Oncology Consultants Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Houston : UT MD Andreson Cancer Center

Preventing Sexual Dysfunction With Aromatase Inhibitors

Houston : Ben Taub General Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Houston : St. Luke's Texas Cancer Institute at St. Luke's Episcopal Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Houston : Veterans Affairs Medical Center - Houston

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Houston : M. D. Anderson Cancer Center at University of Texas

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Houston : Baylor University Medical Center - Houston

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Houston :

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

Houston : Memorial Hermann Hospital

The Study of Biodistribution and Dosimetry of 99mTc-Glycopeptide(99mTc-GP) in Patients With Breast Cancer

Houston : UT MD Anderson Cancer Center

TKI258 for Metastatic Inflammatory Breast Cancer Patients

Houston : UT MD Anderson Cancer Center

TPI 287 in Breast Cancer Metastatic to the Brain

Houston : University of Texas MD Anderson Cancer Center

Vaccine Therapy in Treating Patients With Breast Cancer

Lubbock : Joe Arrington Cancer Research & Treatment Center

Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer

New Braunfels : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Plano : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Plano : Plano Cancer Institute

MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I

San Antonio : Updated

A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer

San Antonio : Cancer Centers of South Texas

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

San Antonio : Kathryn A. Wagner Private Practice

NBRST: Prospective Neo-adjuvant REGISTRY Trial

San Antonio : Radiation Oncology of San Antonio

NBRST: Prospective Neo-adjuvant REGISTRY Trial

San Antonio : Cancer Therapy & Research Center / UT Health Science Center Institute for Drug Development Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

San Antonio : Veterans Affairs Medical Center - San Antonio (Murphy)

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

San Antonio : University of Texas Health Science Center at San Antonio

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

San Antonio : University Hospital - San Antonio

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

San Antonio : Cancer Therapy and Research Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

San Antonio : Cancer Therapy and Research Center

Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors

San Antonio : STOH Clinical Research

Vaccine Therapy in Treating Patients With Breast Cancer

Temple : Updated

A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer

Temple : CCOP - Scott and White Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

The Woodlands : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Tyler : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Tyler :

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

Additional Locations :

An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)

American Fork : American Fork Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Cedar City : Sandra L. Maxwell Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Logan : Logan Regional Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Murray : Jon and Karen Huntsman Cancer Center at Intermountain Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

View More »

Ogden :

A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Patients With Locally Recurrent or Metastatic Breast Cancer

Ogden : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Ogden : Updated

A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer

Ogden : Val and Ann Browning Cancer Center at McKay-Dee Hospital Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Provo : Utah Valley Regional Medical Center - Provo

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Salt Lake City : Utah Cancer Specialists Dept.of Utah Cancer Spec. (3) Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Salt Lake City : LDS Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Salt Lake City : Utah Cancer Specialists at UCS Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Salt Lake City : Huntsman Cancer Institute at University of Utah

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

St. George : Dixie Regional Medical Center - East Campus

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Additional Locations :

An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)

Burlington : Updated

Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

Additional Locations :

An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)

Charlottesville : Virginia Breast Care

NBRST: Prospective Neo-adjuvant REGISTRY Trial

Danville : Research Site Updated

Video Impact on Neulasta Education

Fredericksburg : Updated

A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer

Fredericksburg : Fredericksburg Oncology, Incorporated

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

View More »

Lorton : Surgical Specialists of Northern Virginia

NBRST: Prospective Neo-adjuvant REGISTRY Trial

Lynchburg : Updated

A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)

Lynchburg : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Lynchburg : Lynchburg Hematology Oncology Clinic

NBRST: Prospective Neo-adjuvant REGISTRY Trial

Midlothian : Bon Secours Virginia Breast Center

NBRST: Prospective Neo-adjuvant REGISTRY Trial

Newport News : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Newport News : Sandoz Investigational Site

Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim

Norfolk : Virginia Oncology Associates

PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

Reston : Medical Oncology & Hematology Associates of Northern VA Med Onc Hem Northern VA

A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation

Richmond : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Richmond : Virginia Commonwealth University Massey Cancer Center

Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer

Richmond : Virginia Commonwealth University

Safety Study for Short-course Accelerated, Hypofractionated Partial Breast Radiotherapy (APBI) in Women With Early Stage Breast Cancer Using the Contura MLB

Richmond :

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

Richmond : Virginia Cancer Institute

Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer

Roanoke : Blue Ridge Cancer Care

NBRST: Prospective Neo-adjuvant REGISTRY Trial

Roanoke : Oncology Hematology Associates of Southest Virginia Salem VA Branch Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Winchester :

A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Patients With Locally Recurrent or Metastatic Breast Cancer

Winchester : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Tacoma : MultiCare Health System

Combined Targeted Therapies for Triple Negative Advanced Breast Cancer - A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib

Tacoma : MultiCare Health System

Efficacy and Safety Study of NeuVax(TM) Vaccine to Prevent Breast Cancer Recurrence (PRESENT)

View More »

Additional Locations :

An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)

Anacortes : Island Hospital Cancer Care Center at Island Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Bellingham : St. Joseph Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Bremerton : Olympic Hematology and Oncology

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Burien : Highline Medical Center Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Centralia : Providence Centralia Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Edmonds :

A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Patients With Locally Recurrent or Metastatic Breast Cancer

Everett : Providence Regional Cancer Partnership

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Federal Way : St. Francis Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Issaquah : Swedish Medical Center - Issaquah Campus

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Kennewick : Columbia Basin Hematology Columbia Basin Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Kennewick : Columbia Basin Hematology

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Kirkland : Cascade Cancer Center at Evergreen Hospital Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Mount Vernon : Skagit Valley Hospital Cancer Care Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Olympia : Providence St. Peter Hospital Regional Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Poulsbo : Harrison Poulsbo Hematology and Onocology

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Puyallup : Good Samaritan Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Seattle : Updated

A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer

Seattle : University Cancer Center at University of Washington Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Seattle : CCOP - Virginia Mason Research Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Seattle : Harborview Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Seattle : Virginia Mason Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Seattle : Fred Hutchinson Cancer Research Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Seattle : Swedish Cancer Institute at Swedish Medical Center - First Hill Campus

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Seattle : Minor and James Medical, PLLC

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Seattle : Polyclinic First Hill

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Seattle : Pacific Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Seattle : Group Health Central Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Sedro-Woolley : North Puget Oncology at United General Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Spokane : Rockwood Clinic Rockwood Clinic, PS

Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Spokane : Rockwood Clinic

NBRST: Prospective Neo-adjuvant REGISTRY Trial

Spokane : Cancer Care Northwest CC Northwest- Spokane South Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Spokane : Cancer Care Northwest - Spokane South

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Spokane : Evergreen Hematology and Oncology, PS

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Tacoma : CCOP - Northwest

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Tacoma : Allenmore Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Tacoma : MultiCare Regional Cancer Center at Tacoma General Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Tacoma : Franciscan Cancer Center at St. Joseph Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Tacoma : St. Clare Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Tacoma : Madigan Army Medical Center - Tacoma

Vaccine Therapy in Treating Patients With Breast Cancer

Vancouver : Legacy Salmon Creek Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Vancouver : Southwest Washington Medical Center Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Walla Walla : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Wenatchee : Wenatchee Valley Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Morgantown : West Virginia University - Clinical Trials Research Unit

BIG411-Ph3 Chemo + Herceptin + Placebo / Pertuzumab as Adjuvant Therapy for Operable HER-2 + Breast CA

Morgantown : West Virginia University - Clinical Trials Research Unit

CIRB) NSABP B-43: A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy

Morgantown : West Virginia University - Clinical Trials Research Unit

ECOG5508 - Randomized Phase III Study of Maintenance Therapy with Bevacizumab,Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC

Morgantown : West Virginia University - Clinical Trials Research Unit

GO25632 A Phase III, Randomized, Double-Blind,Placebo-Controlled, Multicenter Study To Evaluate The Efficacy And Safety Of Bevacizumab

Morgantown : West Virginia University - Clinical Trials Research Unit

NSABP-B47 - A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer

Morgantown : West Virginia University - Clinical Trials Research Unit

NSABP-B49 - A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer

Morgantown : West Virginia University - Clinical Trials Research Unit

NSABP-FB7 A Phase II Randomized Clinical Trial Evaluating Neoadjuvant Therapy Regimens

Morgantown : West Virginia University - Clinical Trials Research Unit

NSABP-FB9 A Phase II Randomized Clinical Trial Evaluating Neoadjuvant Chemotherapy Regimens

Morgantown : West Virginia University - Clinical Trials Research Unit

RTOG-1005 - A Phase III Trial of Accelerated Whole Breast Irradiation

View More »

Additional Locations :

An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)

Morgantown : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Morgantown : Updated

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Morgantown : Mary Babb Randolph Cancer Center at West Virginia University Hospitals

Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer

Morgantown : West Virginia University Hospitals Inc.

Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer

Additional Locations :

An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)

Green Bay : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Green Bay : Cancer TEAM Bellin Health Belin Health Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Green Bay : St. Vincent Hospital Regional Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Green Bay : St. Mary's Hospital Medical Center - Green Bay

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

View More »

Green Bay : Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Green Bay : Green Bay Oncology, Limited at St. Mary's Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

La Crosse : Gundersen Lutheran Center for Cancer and Blood

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Madison : Dean Health System Dean Hematology Oncology Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Madison : Updated

Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

Manitowoc : Holy Family Memorial Medical Center Cancer Care Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Marshfield : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Milwaukee : Columbia St. Marys Cancer Center

NBRST: Prospective Neo-adjuvant REGISTRY Trial

Oconto Falls : Green Bay Oncology, Limited - Oconto Falls

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Sheboygan : St. Nicholas Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Sturgeon Bay : Green Bay Oncology, Limited - Sturgeon Bay

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Wauwatosa : Wheaton Franciscan Healthcare

NBRST: Prospective Neo-adjuvant REGISTRY Trial

Additional Locations :

An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)

Casper : Rocky Mountain Oncology

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Tirana : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Algiers : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Buenos Aires : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Buenos Aires : Updated

A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)

Buenos Aires : Updated

A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Breast Cancer Progressing After First-Line Therapy With Avastin and Chemotherapy (TANIA)

Buenos Aires :

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Buenos Aires : Hospital Interzonal General De Agudos EvaPeron

Perioperative Use of Desmopressin (DDAVP) in Breast Cancer

View More »

Buenos Aires : Novartis Investigative Site Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Caba : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Caba : Updated

A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)

Cordoba :

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

La Plata : Updated

A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)

La Plata :

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

La Rioja : Updated

A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE)

Mendoza :

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Quilmes :

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Rio Negro : Novartis Investigative Site Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Rosario : Updated

A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)

Rosario :

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Rosario : Updated

A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE)

Rosario Santa Fe : Synta Pharmaceuticals Investigative Site

A Phase 2 Study Evaluating Ganetespib in Women With Metastatic HER2+ or Triple Negative Breast Cancer

San Miguel de Tucuman : Updated

A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Breast Cancer Progressing After First-Line Therapy With Avastin and Chemotherapy (TANIA)

San Miguel de Tucuman : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Santa Fe : Updated

A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)

Tucuman : Novartis Investigative Site Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Zarate : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Adelaide : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Adelaide : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Auchenflower : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Bedford Park :

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

Camperdown : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

View More »

Canberra : Updated

A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE)

Chermside : Updated

A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE)

Clayton : Novartis Investigative Site Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

East Bentleigh : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Footscray : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Footscray : Updated

A Study of Trastuzumab Emtansine in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment

Frankston : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Frankston :

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

Geelong : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Geelong : Novartis Investigative Site

A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation

Heidelberg : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Hobart : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Kogarah : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Kogarah :

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

Lismore : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Malvern : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Melbourne : Updated

A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE)

Melbourne : Updated

A Study of Trastuzumab Emtansine in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment

Melbourne : Novartis Investigative Site Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Milton : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Milton : Updated

A Study of Trastuzumab Emtansine in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment

Milton :

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

Murdoch : Novartis Investigative Site Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

North Sydney : Updated

A Study of Trastuzumab Emtansine in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment

Parkville : Updated

A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE)

Parkville : Novartis Investigative Site

A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation

Parkville :

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

Perth : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Perth : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Perth : Novartis Investigative Site

A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation

Perth : Novartis Investigative Site Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Sydney : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Sydney : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Sydney : Novartis Investigative Site

A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation

Sydney : Novartis Investigative Site Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Sydney : St George Hospital

STARS Breast Trial (Study of Anastrozole and Radiotherapy Sequencing Pilot)

Sydney : St George Private Hospital

Use of Hair to Diagnose Breast Cancer

Sydney : Penrith Imaging

Use of Hair to Diagnose the Presence of Breast Cancer

Sydney : Diagnostic Imaging Centre, St George Private Hospital

Use of Hair to Diagnose the Presence of Breast Cancer

Sydney : Bankstown Diagnostic Imaging Centre

Use of Hair to Diagnose the Presence of Breast Cancer

Sydney : Campbelltown Ultrascan Radiology

Use of Hair to Diagnose the Presence of Breast Cancer

Sydney : Liverpool Ultrascan Radiology

Use of Hair to Diagnose the Presence of Breast Cancer

Wahroonga :

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

Waratah : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Wodonga : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Woodville :

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

Woolloongabba : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Baden : Research Site

Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy

Bludesch : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Braunau : Research Site

Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy

Dornbirn : Research Site

Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy

Feldkirch : State Hospital Feldkirch, Coop. Group

A Phase II Study of Neoadjuvant Trastuzumab+Docetaxel+NPLD+/-Bevacizumab in Her2-pos. Early Breast Cancer

View More »

Feldkirch : Updated

A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Breast Cancer Progressing After First-Line Therapy With Avastin and Chemotherapy (TANIA)

Feldkirch : Research Site

Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy

Güssing : Research Site

Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy

Gmunden : Research Site

Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy

Graz : Medical University of Graz-Oncology; Coop. Group

A Phase II Study of Neoadjuvant Trastuzumab+Docetaxel+NPLD+/-Bevacizumab in Her2-pos. Early Breast Cancer

Graz : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Graz : Updated

A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE)

Graz : Novartis Investigative Site

A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation

Graz : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Graz : Research Site

Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy

Hall in Tirol : Research Site

Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy

Innsbruck : Gynaegological Medical University Innsbruck

A Phase II Study of Neoadjuvant Trastuzumab+Docetaxel+NPLD+/-Bevacizumab in Her2-pos. Early Breast Cancer

Innsbruck : Updated

A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE)

Innsbruck : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Innsbruck : Research Site

Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy

Klagenfurt : Research Site

Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy

Krems : Updated

A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)

Krems an der Donau : Research Site

Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy

Kufstein : District Hospital Kufstein

A Phase II Study of Neoadjuvant Trastuzumab+Docetaxel+NPLD+/-Bevacizumab in Her2-pos. Early Breast Cancer

Kufstein : Research Site

Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy

Leoben : State Hospital Leoben

A Phase II Study of Neoadjuvant Trastuzumab+Docetaxel+NPLD+/-Bevacizumab in Her2-pos. Early Breast Cancer

Leoben : Research Site

Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy

Lienz : Research Site

Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy

Linz : Hospital BHS Linz, Coop. Study Group

A Phase II Study of Neoadjuvant Trastuzumab+Docetaxel+NPLD+/-Bevacizumab in Her2-pos. Early Breast Cancer

Linz : AKH Linz

A Phase II Study of Neoadjuvant Trastuzumab+Docetaxel+NPLD+/-Bevacizumab in Her2-pos. Early Breast Cancer

Linz : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Linz : Novartis Investigative Site Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Linz : Updated

Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

Linz : Research Site

Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy

Oberpullendorf : Research Site

Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy

Rankweil : Updated

A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)

Ried : Research Site

Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy

Rottenmann : Research Site

Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy

Salzburg : Paracelsus Medical University Salzburg-Oncology, Coop. Group

A Phase II Study of Neoadjuvant Trastuzumab+Docetaxel+NPLD+/-Bevacizumab in Her2-pos. Early Breast Cancer

Salzburg : Updated

A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)

Salzburg : Updated

A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE)

Salzburg : Updated

A Study of Trastuzumab Emtansine in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment

Salzburg : Novartis Investigative Site Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Salzburg : Research Site

Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy

Schärding : Research Site

Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy

St Poelten : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

St Poelten : Research Site

Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy

St Veit An Der Glan : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

St Veit an der Glan : Research Site

Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy

St. Poelten : Research Site

Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy

Steyr : Research Site

Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy

Vöcklabruck : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Vienna : Medical University Vienna, General Hospital

A Phase II Study of Neoadjuvant Trastuzumab+Docetaxel+NPLD+/-Bevacizumab in Her2-pos. Early Breast Cancer

Vienna : Med. Univ. Vienna; General Hospital Vienna

A Phase II Study of Neoadjuvant Trastuzumab+Docetaxel+NPLD+/-Bevacizumab in Her2-pos. Early Breast Cancer

Vienna : State Hospital Vienna-Hietzing

A Phase II Study of Neoadjuvant Trastuzumab+Docetaxel+NPLD+/-Bevacizumab in Her2-pos. Early Breast Cancer

Vienna : Novartis Investigative Site

A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation

Villach : Updated

A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Breast Cancer Progressing After First-Line Therapy With Avastin and Chemotherapy (TANIA)

Villach : Research Site

Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy

Vocklabruck : Research Site

Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy

Weiz : Research Site

Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy

Wels : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Wels : Research Site

Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy

Wien : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Wien : Updated

A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE)

Wien : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Wien : Novartis Investigative Site Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Wien : Updated

Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

Wien : Research Site

Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy

Wiener Neustadt : Research Site

Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy

Wolfsberg : Research Site

Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy

Aalst : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Anderlecht :

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

Antwerp : Universitair Ziekenhuis Antwerpen

An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.

Bonheiden : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Brasschaat : Updated

A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)

View More »

Brasschaat : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Brugge : GSK Investigational Site Updated

ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D

Brugge : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Brussels : Synta Pharmaceuticals Investigative Site

A Phase 2 Study Evaluating Ganetespib in Women With Metastatic HER2+ or Triple Negative Breast Cancer

Brussels : Jules Bordet Institute

An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.

Brussels : Hôpitaux Universitaires Bordet-Erasme - Institut Jules Bordet Updated

Efficacy Study of Herceptin to Treat HER2-negative CTC Breast Cancer

Bruxelles : Updated

A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)

Bruxelles : Updated

A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE)

Bruxelles : Updated

A Study of Trastuzumab Emtansine in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment

Bruxelles : Université

Impact on Cognitive Function and Quality of Life of Adjuvant Chemotherapy in Patients Aged Over 65 Years: Application to Breast Cancer or Colon

Bruxelles : Novartis Investigative Site Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Bruxelles :

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

Charleroi : Synta Pharmaceutical Investigative Site

A Phase 2 Study Evaluating Ganetespib in Women With Metastatic HER2+ or Triple Negative Breast Cancer

Charleroi : Updated

A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)

Charleroi : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Charleroi : Novartis Investigative Site Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Edegem : Updated

A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE)

Edegem : Updated

A Study of Trastuzumab Emtansine in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment

Edegem :

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

Eupen : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Gent : Updated

A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE)

Gent : Updated

A Study of Trastuzumab Emtansine in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment

Ghent :

Study Evaluating the Safety and Efficacy of Onartuzumab (Metmab) And/Or Bevacizumab in Combination With Paclitaxel in Patients With Metastatic, Triple Negative Breast Cancer

Gilly : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Haine-saint-paul : Updated

A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)

Hasselt : Updated

A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)

Jette : Novartis Investigative Site Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Kortrijk : Updated

A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)

Leuven : Updated

A Study of Trastuzumab Emtansine in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment

Leuven : GSK Investigational Site Updated

ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D

Leuven : Novartis Investigative Site Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Leuven : Research Site

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

Leuven :

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

Liege : Novartis Investigative Site

A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer.

Liege : Updated

A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)

Liege : Novartis Investigative Site

A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation

Liege : Updated

A Study of Trastuzumab Emtansine in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment

Liege : Novartis Investigative Site Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Liege : Research Site

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

Liege :

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

Liège : Updated

A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE)

Liège : Novartis Investigative Site

A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation

Liège : GSK Investigational Site Updated

ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D

Mechelen : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Namur : Updated

A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)

Namur : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Namur : Updated

A Study of Trastuzumab Emtansine in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment

Namur : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Namur : Novartis Investigative Site Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Oostende : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Ottignies : Novartis Investigative Site

A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation

Sint-Niklaas : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Verviers : GSK Investigational Site Updated

ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D

Verviers : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Wilrijk : Synta Pharmaceuticals Investigative Site

A Phase 2 Study Evaluating Ganetespib in Women With Metastatic HER2+ or Triple Negative Breast Cancer

Wilrijk : Novartis Investigative Site

A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation

Wilrijk : Updated

A Study of Trastuzumab Emtansine in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment

Wilrijk : Novartis Investigative Site Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Wilrijk : Research Site

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

Banja Luka : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Sarajevo : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Cachoeiro Do Itapemirim : Updated

A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)

Goiania : Updated

A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Breast Cancer Progressing After First-Line Therapy With Avastin and Chemotherapy (TANIA)

Goiânia/Go :

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Ijuí :

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Itajai : Updated

A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Breast Cancer Progressing After First-Line Therapy With Avastin and Chemotherapy (TANIA)

View More »

Porto Alegre : Updated

A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)

Porto Alegre : Updated

A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Breast Cancer Progressing After First-Line Therapy With Avastin and Chemotherapy (TANIA)

Porto Alegre :

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Ribeirão Preto/Sp :

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Santo Andre :

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Sao Jose Do Rio Preto :

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Sao Paulo : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Sao Paulo : Updated

A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)

Sao Paulo : Updated

A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer

Sao Paulo : Updated

A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer

São Paulo- Sp : Updated

A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)

São Paulol :

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Plovdiv : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Plovdiv :

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Sofia : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Sofia :

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Sofia : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

View More »

Sofia : Updated

A Study of Trastuzumab Emtansine in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment

Stara Zagora :

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Varna :

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Varna : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Barrie : Updated

A Study of Trastuzumab Emtansine in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment

Calgary : Novartis Investigative Site Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Cambridge : Novartis Investigative Site Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Edmonton : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Edmonton : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

View More »

Edmonton : Novartis Investigative Site Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Greenfield Park : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Halifax : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Halifax : Novartis Investigative Site Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Hamilton : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Kelowna : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Kelowna : GSK Investigational Site Updated

ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D

Kelowna : Novartis Investigative Site Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Kingston : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Laval : Novartis Investigative Site Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

London : Updated

A Study of Trastuzumab Emtansine in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment

London : Novartis Investigative Site Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Mississauga : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Moncton : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Montreal : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Montreal : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Montreal : Updated

A Study of Trastuzumab Emtansine in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment

Montreal : Updated

A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)

Montreal : Montreal General Hospital

Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer

Montreal : Jewish General Hospital Updated

Neoviderm Skin Emulsion in the Prevention of Radiation Dermatitis

Montreal : University of Montreal Hospital Group

Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer

Montreal : Jewish General Hospital

Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer

Montreal : Novartis Investigative Site Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Montreal : Updated

Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

Montreal :

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

Newmarket : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Newmarket : Updated

A Study of Trastuzumab Emtansine in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment

Newmarket : Novartis Investigative Site Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Oshawa : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Oshawa : Updated

A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)

Ottawa : Novartis Investigative Site Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Quebec : Novartis Investigative Site Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Red Deer : CAMIS - Central Alberta Medical Imaging Services

Adjunctive Efficacy Study Of The SoftScan® Optical Breast Imaging System

Regina : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Regina : Novartis Investigative Site Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Saint John : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Saskatoon :

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

Sherbrooke : GSK Investigational Site Updated

ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D

St Catharines : GSK Investigational Site Updated

ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D

St. Catharines : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

St. John's : Updated

A Study of Trastuzumab Emtansine in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment

Sudbury : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Surrey : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Toronto : Sunnybrook Health Sciences Centre

A Pilot Study To Evaluate the Effectiveness of Pulsed Time-Domain Optical Spectroscopy for Monitoring the Responses in Neoadjuvant Treatments of Locally-Advanced Breast Cancer

Toronto : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Toronto : Updated

A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)

Toronto : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Toronto : Updated

A Study of Trastuzumab Emtansine in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment

Toronto : University Health Network (UNH) - Princess Margaret Hospital

Adjunctive Efficacy Study Of The SoftScan® Optical Breast Imaging System

Toronto : GSK Investigational Site Updated

ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D

Toronto : Novartis Investigative Site Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Toronto : Familial Breast Cancer Research Unit, Women's College Research Institute

The Potential for Oral Diindolylmethane (DIM) Supplementation to Increase the Production of the BRCA1 Protein in BRCA1 Mutation Carriers

Vancouver : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Vancouver : Novartis Investigative Site Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Victoria : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Windsor : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Winnipeg : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Antofagasta : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Paraiso :

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Santiago : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Santiago : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Santiago :

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

View More »

Temuco : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Temuco :

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Temuco :

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

Valparaiso : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Valparaiso :

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

Vina Del Mar :

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

Beijing : Updated

A Study of Herceptin (Trastuzumab) in Combination With a Taxane in Patients With HER2-Positive Breast Cancer Who Relapsed After (Neo)Adjuvant Herceptin Treatment

Beijing : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Beijing : Research Site

Collection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg Treatment

Beijing : Research Site Updated

Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Postmenopausal Women With Advanced Breast Cancer

Beijing : Updated

Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

View More »

Changchun : Research Site

Collection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg Treatment

Changsha : Research Site

Collection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg Treatment

Chendu : Research Site

Collection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg Treatment

Chengdu : Updated

A Study of Herceptin (Trastuzumab) in Combination With a Taxane in Patients With HER2-Positive Breast Cancer Who Relapsed After (Neo)Adjuvant Herceptin Treatment

Chengdu : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Chengdu : Research Site Updated

Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Postmenopausal Women With Advanced Breast Cancer

Chongqing : Research Site Updated

Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Postmenopausal Women With Advanced Breast Cancer

Dalian : Research Site Updated

Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Postmenopausal Women With Advanced Breast Cancer

Fuzhou : Research Site

Collection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg Treatment

Guangdong Province : Updated

A Study of Herceptin (Trastuzumab) in Combination With a Taxane in Patients With HER2-Positive Breast Cancer Who Relapsed After (Neo)Adjuvant Herceptin Treatment

Guangzhou : Updated

A Study of Herceptin (Trastuzumab) in Combination With a Taxane in Patients With HER2-Positive Breast Cancer Who Relapsed After (Neo)Adjuvant Herceptin Treatment

Guangzhou : Research Site

Collection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg Treatment

Guangzhou : Research Site Updated

Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Postmenopausal Women With Advanced Breast Cancer

Guiyang : Research Site

Collection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg Treatment

Hangzhou : Updated

A Study of Herceptin (Trastuzumab) in Combination With a Taxane in Patients With HER2-Positive Breast Cancer Who Relapsed After (Neo)Adjuvant Herceptin Treatment

Hangzhou : Research Site

Collection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg Treatment

Hangzhou : Research Site Updated

Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Postmenopausal Women With Advanced Breast Cancer

Harbin : Updated

A Study of Herceptin (Trastuzumab) in Combination With a Taxane in Patients With HER2-Positive Breast Cancer Who Relapsed After (Neo)Adjuvant Herceptin Treatment

Harbin : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Harbin : Research Site

Collection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg Treatment

Harbin : Research Site Updated

Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Postmenopausal Women With Advanced Breast Cancer

Hefei : Research Site Updated

Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Postmenopausal Women With Advanced Breast Cancer

Huhehaote : Research Site

Collection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg Treatment

Jiangsu : Updated

A Study of Herceptin (Trastuzumab) in Combination With a Taxane in Patients With HER2-Positive Breast Cancer Who Relapsed After (Neo)Adjuvant Herceptin Treatment

Jinan : Research Site Updated

Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Postmenopausal Women With Advanced Breast Cancer

Kunming : Research Site

Collection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg Treatment

Kunshan : Research Site

Collection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg Treatment

Nanjing : Research Site

Collection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg Treatment

Nanjing : Research Site Updated

Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Postmenopausal Women With Advanced Breast Cancer

Nanning : Reseacrh Site Updated

Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Postmenopausal Women With Advanced Breast Cancer

Nanning : Updated

Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

Nantong : Research Site

Collection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg Treatment

Qingdao : Research Site

Collection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg Treatment

Shanghai : Updated

A Study of Herceptin (Trastuzumab) in Combination With a Taxane in Patients With HER2-Positive Breast Cancer Who Relapsed After (Neo)Adjuvant Herceptin Treatment

Shanghai : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Shanghai : Research Site

Collection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg Treatment

Shanghai : Research Site Updated

Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Postmenopausal Women With Advanced Breast Cancer

Shanghai : Cancer Hospital Affiliated to Fudan University

Efficacy and Safety Study of Trastuzumab, Paclitaxel and Carboplatin on HER2+ Preoperative Breast Cancer

Shanghai : Updated

Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

Shanghai : Fudan University Cancer Hospital

Study of Arimidex and Radiotherapy Sequencing

Shenyang : Updated

A Study of Herceptin (Trastuzumab) in Combination With a Taxane in Patients With HER2-Positive Breast Cancer Who Relapsed After (Neo)Adjuvant Herceptin Treatment

Shenyang : Updated

Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

Shijiazhuang : Research Site

Collection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg Treatment

Suzhou : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Taiyuan : Research Site Updated

Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Postmenopausal Women With Advanced Breast Cancer

Tangshan : Research Site

Collection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg Treatment

Tianjin : Research Site

Collection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg Treatment

Tianjin : Research Site Updated

Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Postmenopausal Women With Advanced Breast Cancer

Tianjin : Updated

Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

Weifang : Research Site

Collection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg Treatment

Wuhan : Updated

A Study of Herceptin (Trastuzumab) in Combination With a Taxane in Patients With HER2-Positive Breast Cancer Who Relapsed After (Neo)Adjuvant Herceptin Treatment

Wuhan : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Wuhan : Research Site

Collection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg Treatment

Xi`an : Xijing Hospital ， Fourth Military Medical University

Observational Studies of the Application of Bevacizumab in HER2-negative Breast Cancer Neoadjuvant Chemotherapy

Xi'an : Updated

Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

Yuezhou : Research Site

Collection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg Treatment

Zhengzhou : Updated

A Study of Herceptin (Trastuzumab) in Combination With a Taxane in Patients With HER2-Positive Breast Cancer Who Relapsed After (Neo)Adjuvant Herceptin Treatment

Zhoushan : Research Site

Collection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg Treatment

Bogota : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Cali : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Montería :

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Osijek : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Split : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Split : Updated

An Observational Study of Avastin (Bevacizumab) in Combination With Paclitaxel in First-Line Treatment in Patients With HER2-Negative Metastatic Breast Cancer

Split : Clinical Hospital Split, Center of oncology

Bevacizumab and Capecitabine in Treatment of Elderly Patients With Metastatic Breast Cancer

Split : Center of oncology

Capecitabine and Mitomycin C in Treatment of Patients With Metastatic Breast Cancer

View More »

Varazdin : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Varazdin : Updated

An Observational Study of Avastin (Bevacizumab) in Combination With Paclitaxel in First-Line Treatment in Patients With HER2-Negative Metastatic Breast Cancer

Zagreb : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Zagreb : Updated

A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)

Zagreb : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Brno : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Brno : Updated

A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)

Brno : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Brno : Novartis Investigative Site

A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation

Brno :

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

View More »

Ceske Budejovice : Updated

Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

Hradec Kralove : Updated

A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)

Hradec Kralove : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Nova Ves Pod Plesi : Updated

Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

Nymburk : Updated

Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

Olomouc : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Olomouc : Updated

Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

Olomouc :

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

Pardubice : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Praha : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Praha : Updated

A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)

Praha 10 : Novartis Investigative Site Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Praha 10 : Updated

Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

Praha 2 : Updated

Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

Praha 2 :

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

Praha 5 : Updated

Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

Ves pod Plesi 110 : Insitut Onkologie a Rehabilitaca na Plesi

Phase III Study Comparing the Efficacy and Safety of EP2006 and Filgrastim

Znojmo : Nemocnice Znojmo

Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor

Aalborg : Updated

A Study of Trastuzumab Emtansine in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment

Århus :

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

Copenhagen : Department of Oncology, Rigshospitalet

Vinorelbine Plus (+) Trastuzumab vs Docetaxel Plus (+) Trastuzumab as 1 Line Treatment for HER2 Positive (+) Metastatic Breast Cancer

Herlev : Updated

A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer

Herlev : Updated

A Study of Trastuzumab Emtansine in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment

View More »

Herlev :

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

Herning : Updated

A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer

Hillerød : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Hillerød : Updated

A Study of Trastuzumab Emtansine in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment

København : Updated

A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer

København : Updated

A Study of Trastuzumab Emtansine in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment

København :

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

Naestved : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Odense : Updated

A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer

Odense : Updated

A Study of Trastuzumab Emtansine in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment

Odense :

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

Roskilde : Updated

A Study of Trastuzumab Emtansine in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment

Roskilde :

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

Vejle : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Vejle : Updated

A Study of Trastuzumab Emtansine in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment

Vejle :

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

Cuenca : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Guayaquil : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Quito : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Tepic : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Alexandria : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Cairo : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Tallin : Updated

A Study of Trastuzumab Emtansine in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment

Helsinki : Updated

A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE)

Kuopio : Updated

A Study of Trastuzumab Emtansine in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment

Oulu : Dept of Oncology, Oulu University Hospital

Safety and Efficacy Study of Intravenous Loading Dose of Ibandronate in Breast Cancer Patients

Tampere : Updated

A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE)

Tampere : Updated

A Study of Trastuzumab Emtansine in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment

View More »

Turku : Updated

A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE)

Aix en Provence : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Aix en Provence cedex 01 : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Amiens : Updated

A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE)

Amiens : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Angers Cedex 9 : Novartis Investigative Site

A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation

View More »

Angers Cedex 9 : Novartis Investigative Site Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Avignon Cedex : Novartis Investigative Site Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Bayonne : Updated

A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)

Bayonne : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Besançon Cedex : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Besancon : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Besançon : Updated

A Study of Trastuzumab Emtansine in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment

Bobigny : Updated

A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer

Bordeaux : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Bordeaux : Updated

A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Breast Cancer Progressing After First-Line Therapy With Avastin and Chemotherapy (TANIA)

Bordeaux : Updated

A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer

Bordeaux : Updated

A Study of Trastuzumab Emtansine in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment

Bordeaux : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Bordeaux : Novartis Investigative Site Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Bordeaux : Research Site

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

Boulogne Sur Mer : Updated

A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer

Boulogne sur Mer Cédex : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Bourg En Bresse : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Bourg En Bresse : Updated

A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)

Bourg En Bresse : Updated

A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE)

Bourg en Bresse : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Brest : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Brive : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Brive la Gaillarde : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Caen : Updated

A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer

Caen : CHU

Impact on Cognitive Function and Quality of Life of Adjuvant Chemotherapy in Patients Aged Over 65 Years: Application to Breast Cancer or Colon

Caen : Centre François BACLESSE

Impact on Cognitive Function and Quality of Life of Adjuvant Chemotherapy in Patients Aged Over 65 Years: Application to Breast Cancer or Colon

Caen : INSERM

Impact on Cognitive Function and Quality of Life of Adjuvant Chemotherapy in Patients Aged Over 65 Years: Application to Breast Cancer or Colon

Caen Cedex : Novartis Investigative Site Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Caen Cedex 05 : Research Site

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

Chalon Sur Saone : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Chambery : Centre Hospitalier de Chambery

Evaluation of Homeopathic Treatment for Hot Flashes in Non Metastatic Breast Cancer

Clermont Ferrand : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Clermont Ferrand : Centre Jean Perrin

Evaluation of Homeopathic Treatment for Hot Flashes in Non Metastatic Breast Cancer

Clermont Ferrand : Updated

Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

Clermont-ferrand : Updated

A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Breast Cancer Progressing After First-Line Therapy With Avastin and Chemotherapy (TANIA)

Clermont-Ferrand : Centre Jean Perrin

Assessment of the Efficacy of a Neoadjuvant Combination: "Chemotherapy-targeted Therapy" in Breast Cancer.

Clermont-Ferrand : Novartis Investigative Site Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Colmar Cedex : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Creteil : Updated

A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE)

Creteil : AERO

UFT/LV Maintenance Vs Observation in Metastatic Breast Cancer Responsive to Chemotherapy

Dijon : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Dijon : Updated

A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)

Dijon : Updated

A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE)

Dijon : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Dijon Cedex : Novartis Investigative Site Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Hyeres : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

IVRY sur SEINE : Hôpital Charles FOIX

Impact on Cognitive Function and Quality of Life of Adjuvant Chemotherapy in Patients Aged Over 65 Years: Application to Breast Cancer or Colon

La Roche Sur Yon : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

La Roche sur Yon cedex 9 : Novartis Investigative Site

A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation

La Roche sur Yon cedex 9 : Novartis Investigative Site Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

La Roche Sur Yon Cedex 9 : Research Site

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

La Seyne Sur Mer : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

La Tronche : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Le Mans : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Le Mans Cedex : Novartis Investigative Site

A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation

Le Mans Cedex : Novartis Investigative Site Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Le Mans Cedex 9 : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Lille : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Lille : Centre Oscar Lambret

Assessment of the Efficacy of a Neoadjuvant Combination: "Chemotherapy-targeted Therapy" in Breast Cancer.

Lille : Centre Oscar Lambret

Feasibility Study Of Identification Of Sentinel Node(s) In Breast Cancer

Lille : Hopital gériatrique des Bateliers

Impact on Cognitive Function and Quality of Life of Adjuvant Chemotherapy in Patients Aged Over 65 Years: Application to Breast Cancer or Colon

Lille : CHRU Hôpital Claude Huriez

Impact on Cognitive Function and Quality of Life of Adjuvant Chemotherapy in Patients Aged Over 65 Years: Application to Breast Cancer or Colon

Lille : Université

Impact on Cognitive Function and Quality of Life of Adjuvant Chemotherapy in Patients Aged Over 65 Years: Application to Breast Cancer or Colon

Lille : Updated

Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

Lille Cedex : Novartis Investigative Site Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Limoges : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Limoges : Updated

A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE)

Limoges : Updated

A Study of Trastuzumab Emtansine in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment

Longjumeau cedex 1 : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Lyon : Updated

A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)

Lyon : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Lyon : Updated

A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE)

Lyon : Updated

A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer

Lyon : Updated

A Study of Trastuzumab Emtansine in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment

Lyon : Centre Leon Berard

Evaluation of Homeopathic Treatment for Hot Flashes in Non Metastatic Breast Cancer

Marseille : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Marseille : Updated

A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer

Marseille : Novartis Investigative Site

A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation

Marseille : Updated

A Study of Trastuzumab Emtansine in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment

Marseille : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Marseille : Research Site

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

Mont de Marsan : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Montbeliard : GSK Investigational Site Updated

ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D

Montelimar : Centre Hospitalier de Montelimar

Evaluation of Homeopathic Treatment for Hot Flashes in Non Metastatic Breast Cancer

Montluçon : Centre Hospitalier

Assessment of the Efficacy of a Neoadjuvant Combination: "Chemotherapy-targeted Therapy" in Breast Cancer.

Montpellier : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Montpellier : Novartis Investigative Site Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Mougins : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Mougins : Updated

A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE)

Nancy : Updated

A Study of Avastin (Bevacizumab) Added to Herceptin (Trastuzumab) Plus Docetaxel in the Neoadjuvant Setting in Patients With Early Stage HER2-Positive Breast Cancer

Nancy : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Nantes : Updated

A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer

Nantes : Updated

Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

Nantes Cedex 2 : Research Site

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

Neuilly-sur-seine : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Neuilly-sur-seine : Updated

A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE)

Nice : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Nice : Updated

A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)

Nice : Updated

A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer

Nice Cedex 2 : Novartis Investigative Site

A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation

Nice Cedex 2 : GSK Investigational Site Updated

ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D

Nice Cedex 2 : Novartis Investigative Site Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Nimes : Updated

A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Patients With HER2-Positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-Directed Therapy (TH3RESA)

Périgueux cedex : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Paris : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Paris : Updated

A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)

Paris : Updated

A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE)

Paris : Updated

A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer

Paris : Updated

A Study of Trastuzumab Emtansine in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment

Paris : Updated

A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function

Paris : Hopital TENON

Impact on Cognitive Function and Quality of Life of Adjuvant Chemotherapy in Patients Aged Over 65 Years: Application to Breast Cancer or Colon

Paris : Hopital Pitié-Sapètrière

Impact on Cognitive Function and Quality of Life of Adjuvant Chemotherapy in Patients Aged Over 65 Years: Application to Breast Cancer or Colon

Paris : Hôpital Saint-Louis

Impact on Cognitive Function and Quality of Life of Adjuvant Chemotherapy in Patients Aged Over 65 Years: Application to Breast Cancer or Colon

Paris : Hôpital Européen Georges Pompidou - Service Oncologie Médicale

Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor

Paris : Novartis Investigative Site Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Paris : Pitié Salpêtrière Hospital

Prolactin Receptor and Breast Diseases

Paris :

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

Paris Cedex 20 : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

PAU : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Perigueux : Updated

A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer

Perpignan : Updated

A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE)

Perpignan : Updated

A Study of Trastuzumab Emtansine in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment

Pierre Bénite Cedex : Research Site

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

Pierre Benite : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Pontoise Cedex : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Pringy : Centre Hospitalier d'Annecy

Evaluation of Homeopathic Treatment for Hot Flashes in Non Metastatic Breast Cancer

Pringy Cedex : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Reims : Updated

A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)

Reims : Updated

A Study of Trastuzumab Emtansine in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment

Reims : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Reims Cedex : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Rennes : Updated

A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE)

Rennes : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Roanne : Centre Hospitalier de Roanne

Evaluation of Homeopathic Treatment for Hot Flashes in Non Metastatic Breast Cancer

Rouen : Updated

A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)

Rouen : Updated

A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer

Rouen : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Rouen : CHU

Impact on Cognitive Function and Quality of Life of Adjuvant Chemotherapy in Patients Aged Over 65 Years: Application to Breast Cancer or Colon

Rouen : Centre Henri BECQUEREL

Impact on Cognitive Function and Quality of Life of Adjuvant Chemotherapy in Patients Aged Over 65 Years: Application to Breast Cancer or Colon

Rouen : CHU, Hôpital Bois Guillaume

Impact on Cognitive Function and Quality of Life of Adjuvant Chemotherapy in Patients Aged Over 65 Years: Application to Breast Cancer or Colon

Rouen Cedex 1 : Novartis Investigative Site Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Saint Brieuc : Updated

A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer

Saint Cloud : Updated

A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE)

Saint Cloud : Updated

Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

Saint Grégoire cedex : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Saint Gregoire : Updated

A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE)

Saint Herblain : Updated

A Study of Trastuzumab Emtansine in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment

Saint Herblain cedex : Novartis Investigative Site

A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation

Saint Jean : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Saint Jean : Updated

A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Breast Cancer Progressing After First-Line Therapy With Avastin and Chemotherapy (TANIA)

Saint Priest en Jarez : Institut de Cancérologie de la LOIRE

Assessment of the Efficacy of a Neoadjuvant Combination: "Chemotherapy-targeted Therapy" in Breast Cancer.

Saint Priest en Jarez Cedex : Novartis Investigative Site Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Saint Quentin : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Saint Quentin : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Saint-Herblain Cédex : Novartis Investigative Site Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Saint-priest-en-jarez : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Senlis : Updated

A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer

Soissons Cedex : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Soyaux : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

St Brieuc : Clinique Armoricaine de radiologie

Evaluation of Homeopathic Treatment for Hot Flashes in Non Metastatic Breast Cancer

St Cloud : Updated

A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)

St Cloud : Updated

A Study of Trastuzumab Emtansine in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment

St Priest en Jarez : Institut de Cancérologie Lucien Neuwirth

Evaluation of Homeopathic Treatment for Hot Flashes in Non Metastatic Breast Cancer

Strasbourg : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Strasbourg : Updated

A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)

Strasbourg : GSK Investigational Site Updated

ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D

Strasbourg : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Strasbourg : Hopitaux universitaires

Impact on Cognitive Function and Quality of Life of Adjuvant Chemotherapy in Patients Aged Over 65 Years: Application to Breast Cancer or Colon

Strasbourg cedex : Novartis Investigative Site Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Thonon les Bains : Hôpital Georges Pianta

Assessment of the Efficacy of a Neoadjuvant Combination: "Chemotherapy-targeted Therapy" in Breast Cancer.

Toulouse : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Toulouse : Updated

A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)

Toulouse : Updated

A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Breast Cancer Progressing After First-Line Therapy With Avastin and Chemotherapy (TANIA)

Toulouse : Updated

A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer

Toulouse : Updated

A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Patients With HER2-Positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-Directed Therapy (TH3RESA)

Toulouse : Updated

A Study of Trastuzumab Emtansine in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment

Toulouse : Updated

Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

Toulouse : Research Site

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

Toulouse Cedex 3 : Novartis Investigative Site

A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation

Toulouse Cedex 3 : Novartis Investigative Site Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Valence : Centre Hospitalier de Valence

Evaluation of Homeopathic Treatment for Hot Flashes in Non Metastatic Breast Cancer

Valenciennes : Updated

A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE)

Vandoeuvre-les-nancy : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Vandoeuvre-les-nancy : Updated

A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer

Vichy cedex : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Villefranche Sur Saone Cedex : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Villejuif : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Villejuif Cedex : Novartis Investigative Site

A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation

Villejuif Cedex : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Villejuif Cedex : Novartis Investigative Site Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Tbilisi :

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Tbilisi :

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Amberg : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Ansbach : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Augsburg : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Augsburg : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Bad Soden : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

View More »

Bamberg : Updated

A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE)

Bergisch Gladbach : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Berlin : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Berlin : Updated

A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)

Berlin : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Berlin : Updated

A Study of Trastuzumab Emtansine in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment

Berlin : Updated

A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)

Berlin : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Berlin : Charité, university medicine, Berlin, CCM

Everolimus (RAD001) and Carboplatin in Pretreated Metastatic Breast Cancer

Berlin : Novartis Investigative Site Updated

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

Berlin :

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

Bielefeld : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Bielefeld : Updated

A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Bielefeld : Updated

A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)

Boblingen : Updated

A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)

Böblingen : Updated

A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)

Bochum : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Bottrop : Marienhospital

Study of ExAblate Focused Ultrasound Ablation of Breast Cancer

Bremen : Updated

A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)

Bremen : Updated

A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE)

Bremerhaven : Updated

A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer)

Bremerhaven : Updated

A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PER